(X) | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
( ) | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Philip Morris International Inc. | ||||
Virginia | 13-3435103 |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
120 Park Avenue New York, New York | 10017 |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code | (917) 663-2000 |
Page No. | ||
PART I - | ||
Item 1. | ||
Condensed Consolidated Statements of Earnings for the | ||
Three Months Ended March 31, 2019 and 2018 | ||
Condensed Consolidated Statements of Comprehensive Earnings for the | ||
Three Months Ended March 31, 2019 and 2018 | ||
Condensed Consolidated Balance Sheets at | ||
March 31, 2019 and December 31, 2018 | ||
Condensed Consolidated Statements of Cash Flows for the | ||
Three Months Ended March 31, 2019 and 2018 | ||
Condensed Consolidated Statements of Stockholders’ (Deficit) Equity for the | ||
Three Months Ended March 31, 2019 and 2018 | ||
Item 2. | ||
Item 4. | ||
PART II - | ||
Item 1. | ||
Item 1A. | ||
Item 2. | ||
Item 6. | ||
For the Three Months Ended March 31, | |||||||
2019 | 2018 | ||||||
Revenues including excise taxes | $ | 17,705 | $ | 18,426 | |||
Excise taxes on products | 10,954 | 11,530 | |||||
Net revenues | 6,751 | 6,896 | |||||
Cost of sales | 2,465 | 2,615 | |||||
Gross profit | 4,286 | 4,281 | |||||
Marketing, administration and research costs (Notes 19 & 20) | 2,217 | 1,833 | |||||
Amortization of intangibles | 19 | 22 | |||||
Operating income | 2,050 | 2,426 | |||||
Interest expense, net | 152 | 227 | |||||
Pension and other employee benefit costs (Note 3) | 21 | 6 | |||||
Earnings before income taxes | 1,877 | 2,193 | |||||
Provision for income taxes | 424 | 559 | |||||
Equity investments and securities (income)/loss, net | (11 | ) | (13 | ) | |||
Net earnings | 1,464 | 1,647 | |||||
Net earnings attributable to noncontrolling interests | 110 | 91 | |||||
Net earnings attributable to PMI | $ | 1,354 | $ | 1,556 | |||
Per share data (Note 6): | |||||||
Basic earnings per share | $ | 0.87 | $ | 1.00 | |||
Diluted earnings per share | $ | 0.87 | $ | 1.00 |
For the Three Months Ended March 31, | ||||||||
2019 | 2018 | |||||||
Net earnings | $ | 1,464 | $ | 1,647 | ||||
Other comprehensive earnings (losses), net of income taxes: | ||||||||
Change in currency translation adjustments: | ||||||||
Unrealized gains (losses), net of income taxes of ($128) in 2019 and $192 in 2018 | 286 | (371 | ) | |||||
(Gains)/losses transferred to earnings - deconsolidation of RBH, net of income taxes of $- in 2019 and $- in 2018 (Note 20) | 502 | — | ||||||
Change in net loss and prior service cost: | ||||||||
Amortization of net losses, prior service costs and net transition costs, net of income taxes of ($4) in 2019 and ($11) in 2018 | 63 | 50 | ||||||
(Gains)/losses transferred to earnings - deconsolidation of RBH, net of income taxes of ($15) in 2019 and $- in 2018 (Note 20) | 27 | — | ||||||
Change in fair value of derivatives accounted for as hedges: | ||||||||
Gains (losses) recognized, net of income taxes of $1 in 2019 and $10 in 2018 | (1 | ) | (64 | ) | ||||
(Gains) losses transferred to earnings, net of income taxes of $1 in 2019 and ($1) in 2018 | (4 | ) | 2 | |||||
Total other comprehensive earnings (losses) | 873 | (383 | ) | |||||
Total comprehensive earnings | 2,337 | 1,264 | ||||||
Less comprehensive earnings attributable to: | ||||||||
Noncontrolling interests | 109 | 56 | ||||||
Comprehensive earnings attributable to PMI | $ | 2,228 | $ | 1,208 |
March 31, 2019 | December 31, 2018 | ||||||
ASSETS | |||||||
Cash and cash equivalents | $ | 3,081 | $ | 6,593 | |||
Trade receivables (less allowances of $25 in 2019 and $25 in 2018) | 2,958 | 2,950 | |||||
Other receivables | 577 | 614 | |||||
Inventories: | |||||||
Leaf tobacco | 2,294 | 2,318 | |||||
Other raw materials | 1,548 | 1,405 | |||||
Finished product | 4,476 | 5,081 | |||||
8,318 | 8,804 | ||||||
Other current assets | 807 | 481 | |||||
Total current assets | 15,741 | 19,442 | |||||
Property, plant and equipment, at cost | 14,299 | 14,557 | |||||
Less: accumulated depreciation | 7,405 | 7,356 | |||||
6,894 | 7,201 | ||||||
Goodwill (Note 4) | 5,775 | 7,189 | |||||
Other intangible assets, net (Note 4) | 2,129 | 2,278 | |||||
Investments in unconsolidated subsidiaries and equity securities (Notes 11&14) | 4,578 | 1,269 | |||||
Deferred income taxes | 951 | 977 | |||||
Other assets | 1,974 | 1,445 | |||||
TOTAL ASSETS | $ | 38,042 | $ | 39,801 |
March 31, 2019 | December 31, 2018 | ||||||
LIABILITIES | |||||||
Short-term borrowings (Note 10) | $ | 1,551 | $ | 730 | |||
Current portion of long-term debt (Note 10) | 5,582 | 4,054 | |||||
Accounts payable | 1,812 | 2,068 | |||||
Accrued liabilities: | |||||||
Marketing and selling | 580 | 732 | |||||
Taxes, except income taxes | 4,354 | 5,088 | |||||
Employment costs | 713 | 794 | |||||
Dividends payable | 1,783 | 1,783 | |||||
Other | 1,741 | 1,366 | |||||
Income taxes | 370 | 576 | |||||
Total current liabilities | 18,486 | 17,191 | |||||
Long-term debt (Note 10) | 23,131 | 26,975 | |||||
Deferred income taxes | 921 | 898 | |||||
Employment costs | 2,958 | 3,083 | |||||
Income taxes and other liabilities | 2,731 | 2,393 | |||||
Total liabilities | 48,227 | 50,540 | |||||
Contingencies (Note 8) | |||||||
STOCKHOLDERS’ (DEFICIT) EQUITY | |||||||
Common stock, no par value (2,109,316,331 shares issued in 2019 and 2018) | — | — | |||||
Additional paid-in capital | 1,907 | 1,939 | |||||
Earnings reinvested in the business | 30,588 | 31,014 | |||||
Accumulated other comprehensive losses | (9,237 | ) | (10,111 | ) | |||
23,258 | 22,842 | ||||||
Less: cost of repurchased stock (553,520,033 and 554,736,610 shares in 2019 and 2018, respectively) | 35,226 | 35,301 | |||||
Total PMI stockholders’ deficit | (11,968 | ) | (12,459 | ) | |||
Noncontrolling interests | 1,783 | 1,720 | |||||
Total stockholders’ deficit | (10,185 | ) | (10,739 | ) | |||
TOTAL LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY | $ | 38,042 | $ | 39,801 |
For the Three Months Ended March 31, | |||||||
2019 | 2018 | ||||||
CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES | |||||||
Net earnings | $ | 1,464 | $ | 1,647 | |||
Adjustments to reconcile net earnings to operating cash flows: | |||||||
Depreciation and amortization | 240 | 242 | |||||
Deferred income tax (benefit) provision | (94 | ) | 26 | ||||
Cash effects of changes in: | |||||||
Receivables, net | 4 | (113 | ) | ||||
Inventories | 237 | 338 | |||||
Accounts payable | (7 | ) | (62 | ) | |||
Accrued liabilities and other current assets | (855 | ) | (509 | ) | |||
Income taxes | (251 | ) | (315 | ) | |||
Pension plan contributions | (17 | ) | (25 | ) | |||
Other | 520 | (1) | 151 | ||||
Net cash provided by operating activities | 1,241 | 1,380 | |||||
CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES | |||||||
Capital expenditures | (324 | ) | (365 | ) | |||
Investments in unconsolidated subsidiaries and equity securities | (24 | ) | (18 | ) | |||
Deconsolidation of RBH (Note 20) | (1,346 | ) | (2) | — | |||
Net investment hedges | 91 | (665 | ) | ||||
Other | 7 | 30 | |||||
Net cash used in investing activities | (1,596 | ) | (1,018 | ) |
For the Three Months Ended March 31, | |||||||
2019 | 2018 | ||||||
CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES | |||||||
Short-term borrowing activity by original maturity: | |||||||
Net issuances - maturities of 90 days or less | $ | (167 | ) | $ | 103 | ||
Issuances - maturities longer than 90 days | 989 | — | |||||
Long-term debt repaid | (2,137 | ) | — | ||||
Dividends paid | (1,780 | ) | (1,659 | ) | |||
Sale (purchase) of subsidiary shares to/(from) noncontrolling interests (Note 17) | — | (91 | ) | ||||
Other | (56 | ) | (91 | ) | |||
Net cash used in financing activities | (3,151 | ) | (1,738 | ) | |||
Effect of exchange rate changes on cash, cash equivalents and restricted cash | (28 | ) | 131 | ||||
Cash, cash equivalents and restricted cash(3): | |||||||
Increase (Decrease) | (3,534 | ) | (1,245 | ) | |||
Balance at beginning of period | 6,620 | 8,476 | |||||
Balance at end of period | $ | 3,086 | $ | 7,231 | |||
PMI Stockholders’ (Deficit) Equity | |||||||||||||||||||||||||||
Common Stock | Additional Paid-in Capital | Earnings Reinvested in the Business | Accumulated Other Comprehensive Losses | Cost of Repurchased Stock | Noncontrolling Interests | Total | |||||||||||||||||||||
Balances, January 1, 2018 | $ | — | $ | 1,972 | $ | 29,859 | $ | (8,535 | ) | $ | (35,382 | ) | $ | 1,856 | $ | (10,230 | ) | ||||||||||
Net earnings | 1,556 | 91 | 1,647 | ||||||||||||||||||||||||
Other comprehensive earnings (losses), net of income taxes | (344 | ) | (39 | ) | (383 | ) | |||||||||||||||||||||
Issuance of stock awards | (29 | ) | 74 | 45 | |||||||||||||||||||||||
Dividends declared ($1.07 per share) | (1,668 | ) | (1,668 | ) | |||||||||||||||||||||||
Payments to noncontrolling interests | (36 | ) | (36 | ) | |||||||||||||||||||||||
Adoption of new accounting standards | 238 | 238 | |||||||||||||||||||||||||
Other (Note 17) | (87 | ) | (4 | ) | (4 | ) | (95 | ) | |||||||||||||||||||
Balances, March 31, 2018 | $ | — | $ | 1,856 | $ | 29,985 | $ | (8,883 | ) | $ | (35,308 | ) | $ | 1,868 | $ | (10,482 | ) | ||||||||||
Balances, January 1, 2019 | $ | — | $ | 1,939 | $ | 31,014 | $ | (10,111 | ) | $ | (35,301 | ) | $ | 1,720 | $ | (10,739 | ) | ||||||||||
Net earnings | 1,354 | 110 | 1,464 | ||||||||||||||||||||||||
Other comprehensive earnings (losses), net of income taxes | 345 | (1 | ) | 344 | |||||||||||||||||||||||
Issuance of stock awards | (32 | ) | 75 | 43 | |||||||||||||||||||||||
Dividends declared ($1.14 per share) | (1,780 | ) | (1,780 | ) | |||||||||||||||||||||||
Payments to noncontrolling interests | (46 | ) | (46 | ) | |||||||||||||||||||||||
Deconsolidation of RBH (Note 20) | 529 | 529 | |||||||||||||||||||||||||
Balances, March 31, 2019 | $ | — | $ | 1,907 | $ | 30,588 | $ | (9,237 | ) | $ | (35,226 | ) | $ | 1,783 | $ | (10,185 | ) |
Number of Shares Granted | Weighted-Average Grant Date Fair Value Per RSU Award Granted | Compensation Expense Related to RSU Awards (in millions) | ||||||||
2019 | 1,621,070 | $ | 77.13 | $ | 36 | |||||
2018 | 1,249,650 | $ | 100.70 | $ | 38 |
Number of Shares Granted | PSU Grant Date Fair Value Subject to Other Performance Factors Per Share | PSU Grant Date Fair Value Subject to TSR Performance Factor Per Share | Compensation Expense Related to PSU Awards (in millions) | ||||||||
2019 | 625,200 | $ | 77.20 | $ | 83.59 | $ | 18 | ||||
2018 | 401,500 | $ | 100.69 | $ | 118.98 | $ | 21 |
2019 | 2018 | |||||
Risk-free interest rate (a) | 2.4 | % | 2.3 | % | ||
Expected volatility | 21.4 | % | (b) | 19.6 | % | (c) |
For the Three Months Ended March 31, | |||||||
(in millions) | 2019 | 2018 | |||||
Net pension costs (income) | $ | (5 | ) | $ | (16 | ) | |
Net postemployment costs | 24 | 19 | |||||
Net postretirement costs | 2 | 3 | |||||
Total pension and other employee benefit costs | $ | 21 | $ | 6 |
Pension (1) | |||||||
For the Three Months Ended March 31, | |||||||
(in millions) | 2019 | 2018 | |||||
Service cost | $ | 54 | $ | 53 | |||
Interest cost | 29 | 28 | |||||
Expected return on plan assets | (79 | ) | (87 | ) | |||
Amortization: | |||||||
Net loss | 45 | 43 | |||||
Prior service cost | — | — | |||||
Net periodic pension cost | $ | 49 | $ | 37 |
(in millions) | European Union | Eastern Europe | Middle East & Africa | South & Southeast Asia | East Asia & Australia | Latin America & Canada | Total | ||||||||||||||
Balances, December 31, 2018 | 1,357 | 303 | 87 | 2,795 | 536 | 2,111 | 7,189 | ||||||||||||||
Changes due to: | |||||||||||||||||||||
Currency | (18 | ) | (3 | ) | (1 | ) | 35 | 5 | 31 | 49 | |||||||||||
Deconsolidation of RBH | (1,463 | ) | (1,463 | ) | |||||||||||||||||
Balances, March 31, 2019 | $ | 1,339 | $ | 300 | $ | 86 | $ | 2,830 | $ | 541 | $ | 679 | $ | 5,775 |
March 31, 2019 | December 31, 2018 | |||||||||||||||||||
(in millions) | Weighted-Average Remaining Useful Life | Gross Carrying Amount | Accumulated Amortization | Net | Gross Carrying Amount | Accumulated Amortization | Net | |||||||||||||
Non-amortizable intangible assets | $ | 1,289 | $ | 1,289 | $ | 1,269 | $ | 1,269 | ||||||||||||
Amortizable intangible assets: | ||||||||||||||||||||
Trademarks | 18 years | 1,217 | $ | 489 | 728 | 1,488 | $ | 608 | 880 | |||||||||||
Distribution networks | 8 years | 111 | 66 | 45 | 141 | 82 | 59 | |||||||||||||
Other* | 10 years | 106 | 39 | 67 | 107 | 37 | 70 | |||||||||||||
Total other intangible assets | $ | 2,723 | $ | 594 | $ | 2,129 | $ | 3,005 | $ | 727 | $ | 2,278 |
Derivative Assets | Derivative Liabilities | |||||||||||||||||||
Fair Value | Fair Value | |||||||||||||||||||
(in millions) | Balance Sheet Classification | At March 31, 2019 | At December 31, 2018 | Balance Sheet Classification | At March 31, 2019 | At December 31, 2018 | ||||||||||||||
Derivative contracts designated as hedging instruments | Other current assets | $ | 278 | $ | 54 | Other accrued liabilities | $ | 55 | $ | 47 | ||||||||||
Other assets | 42 | 99 | Other liabilities | 447 | 525 | |||||||||||||||
Derivative contracts not designated as hedging instruments | Other current assets | 39 | 67 | Other accrued liabilities | 44 | 46 | ||||||||||||||
Other assets | — | — | Other liabilities | 20 | 13 | |||||||||||||||
Total derivatives | $ | 359 | $ | 220 | $ | 566 | $ | 631 |
(pre-tax, in millions) | For the Three Months Ended March 31, | ||||||||||||||||
Amount of Gain/(Loss) Recognized in Other Comprehensive Earnings/(Losses) on Derivatives | Statement of Earnings Classification of Gain/(Loss) Reclassified from Other Comprehensive Earnings/(Losses) into Earnings | Amount of Gain/(Loss) Reclassified from Other Comprehensive Earnings/(Losses) into Earnings | |||||||||||||||
2019 | 2018 | 2019 | 2018 | ||||||||||||||
Derivatives in Cash Flow Hedging Relationship | |||||||||||||||||
Derivative contracts | $ | (2 | ) | $ | (74 | ) | |||||||||||
Net revenues | $ | 10 | $ | (9 | ) | ||||||||||||
Cost of sales | — | — | |||||||||||||||
Marketing, administration and research costs | (3 | ) | 8 | ||||||||||||||
Interest expense, net | (2 | ) | (2 | ) | |||||||||||||
Derivatives in Net Investment Hedging Relationship | |||||||||||||||||
Derivative contracts | 211 | (608 | ) | ||||||||||||||
Total | $ | 209 | $ | (682 | ) | $ | 5 | $ | (3 | ) |
(in millions) | For the Three Months Ended March 31, | |||||
2019 | 2018 | |||||
Gain as of January 1, | $ | 35 | $ | 42 | ||
Derivative (gains)/losses transferred to earnings | (4 | ) | 2 | |||
Change in fair value | (1 | ) | (64 | ) | ||
Gain/(loss) as of March 31, | $ | 30 | $ | (20 | ) |
(in millions) | For the Three Months Ended March 31, | |||||
2019 | 2018 | |||||
Net earnings attributable to PMI | $ | 1,354 | $ | 1,556 | ||
Less distributed and undistributed earnings attributable to share-based payment awards | 4 | 3 | ||||
Net earnings for basic and diluted EPS | $ | 1,350 | $ | 1,553 | ||
Weighted-average shares for basic EPS | 1,555 | 1,553 | ||||
Plus contingently issuable performance stock units (PSUs) | 1 | 1 | ||||
Weighted-average shares for diluted EPS | 1,556 | 1,554 |
(in millions) | For the Three Months Ended March 31, | |||||
2019 | 2018 | |||||
Net revenues: | ||||||
European Union | $ | 2,159 | $ | 1,988 | ||
Eastern Europe | 579 | 567 | ||||
Middle East & Africa | 927 | 961 | ||||
South & Southeast Asia | 1,113 | 1,081 | ||||
East Asia & Australia | 1,321 | 1,591 | ||||
Latin America & Canada | 652 | 708 | ||||
Net revenues | $ | 6,751 | $ | 6,896 | ||
Operating income (loss): | ||||||
European Union | $ | 896 | $ | 740 | ||
Eastern Europe | 129 | 151 | ||||
Middle East & Africa | 344 | 374 | ||||
South & Southeast Asia | 440 | 429 | ||||
East Asia & Australia | 427 | 515 | ||||
Latin America & Canada | (186 | ) | 217 | |||
Operating income | $ | 2,050 | $ | 2,426 |
• | Asset impairment and exit costs - See Note 19. Asset Impairment and Exit Costs for details of the $20 million pre-tax charge included in the South & Southeast Asia segment for the three months ended March 31, 2019. |
• | Canadian tobacco litigation-related expense - See Note 8. Contingencies and Note 20. Deconsolidation of RBH for details of the $194 million pre-tax charge included in the Latin America & Canada segment for the three months ended March 31, 2019. |
• | Loss on deconsolidation of RBH - See Note 20. Deconsolidation of RBH for details of the $239 million loss included in the Latin America & Canada segment for the three months ended March 31, 2019. |
(in millions) | For the Three Months Ended March 31, | |||||
2019 | 2018 | |||||
Net revenues: | ||||||
Combustible products: | ||||||
European Union | $ | 1,812 | $ | 1,836 | ||
Eastern Europe | 471 | 527 | ||||
Middle East & Africa | 829 | 884 | ||||
South & Southeast Asia | 1,113 | 1,081 | ||||
East Asia & Australia | 638 | 737 | ||||
Latin America & Canada | 646 | 704 | ||||
Total combustible products | $ | 5,508 | $ | 5,769 | ||
Reduced-risk products: | ||||||
European Union | $ | 347 | $ | 152 | ||
Eastern Europe | 108 | 40 | ||||
Middle East & Africa | 98 | 77 | ||||
South & Southeast Asia | — | — | ||||
East Asia & Australia | 683 | 854 | ||||
Latin America & Canada | 6 | 4 | ||||
Total reduced-risk products | $ | 1,243 | $ | 1,127 | ||
Total PMI net revenues | $ | 6,751 | $ | 6,896 |
Type of Case | Number of Cases Pending as of April 23, 2019 | Number of Cases Pending as of April 24, 2018 | Number of Cases Pending as of April 25, 2017 | |||
Individual Smoking and Health Cases | 53 | 62 | 63 | |||
Smoking and Health Class Actions | 10 | 11 | 11 | |||
Health Care Cost Recovery Actions | 16 | 16 | 16 | |||
Label-Related Class Actions | 1 | 1 | — | |||
Individual Label-Related Cases | 7 | 1 | 1 | |||
Public Civil Actions | 2 | 2 | 2 |
Date | Location of Court/Name of Plaintiff | Type of Case | Verdict | Post-Trial Developments | ||||
February 2004 | Brazil/The Smoker Health Defense Association | Class Action | The Civil Court of São Paulo found defendants liable without hearing evidence. In April 2004, the court awarded “moral damages” of R$1,000 (approximately $255) per smoker per full year of smoking plus interest at the rate of 1% per month, as of the date of the ruling. The court did not assess actual damages, which were to be assessed in a second phase of the case. The size of the class was not defined in the ruling. | Defendants appealed to the São Paulo Court of Appeals, which annulled the ruling in November 2008, finding that the trial court had inappropriately ruled without hearing evidence and returned the case to the trial court for further proceedings. In May 2011, the trial court dismissed the claim. In March 2017, plaintiff filed an en banc appeal to the Superior Court of Justice. In addition, the defendants filed a constitutional appeal to the Federal Supreme Tribunal on the basis that plaintiff did not have standing to bring the lawsuit. Both appeals are still pending. |
Date | Location of Court/Name of Plaintiff | Type of Case | Verdict | Post-Trial Developments | ||||
May 27, 2015 | Canada/Conseil Québécois Sur Le Tabac Et La Santé and Jean-Yves Blais | Class Action | On May 27, 2015, the Superior Court of the District of Montreal, Province of Quebec ruled in favor of the Blais class on liability and found the class members’ compensatory damages totaled approximately CAD 15.5 billion (approximately $11.6 billion), including pre-judgment interest. The trial court awarded compensatory damages on a joint and several liability basis, allocating 20% to our subsidiary (approximately CAD 3.1 billion including pre-judgment interest (approximately $2.32 billion)). The trial court awarded CAD 90,000 (approximately $67,370) in punitive damages, allocating CAD 30,000 (approximately $22,460) to our subsidiary. The trial court ordered defendants to pay CAD 1 billion (approximately $748.6 million) of the compensatory damage award, CAD 200 million (approximately $149.7 million) of which is our subsidiary’s portion, into a trust within 60 days. | In June 2015, RBH commenced the appellate process with the Court of Appeal of Quebec. On March 1 2019, the Court of Appeal issued a decision largely affirming the trial court's decision. (See “Stayed Litigation — Canada” for further detail.) |
Date | Location of Court/Name of Plaintiff | Type of Case | Verdict | Post-Trial Developments | ||||
May 27, 2015 | Canada/Cecilia Létourneau | Class Action | On May 27, 2015, the Superior Court of the District of Montreal, Province of Quebec ruled in favor of the Létourneau class on liability and awarded a total of CAD 131 million (approximately $98.1 million) in punitive damages, allocating CAD 46 million (approximately $34.4 million) to RBH. The trial court ordered defendants to pay the full punitive damage award into a trust within 60 days. The court did not order the payment of compensatory damages. | In June 2015, RBH commenced the appellate process with the Court of Appeal of Quebec. On March 1, 2019, the Court of Appeal issued a decision largely affirming the trial court's decision. (See “Stayed Litigation — Canada” for further detail.) |
Date | Location of Court/Name of Plaintiff | Type of Case | Verdict | Post-Trial Developments | ||||
August 5, 2016 | Argentina/Hugo Lespada | Individual Action | On August 5, 2016, the Civil Court No. 14 - Mar del Plata, issued a verdict in favor of plaintiff, an individual smoker, and awarded him ARS 110,000 (approximately $2,628), plus interest, in compensatory and moral damages. The trial court found that our subsidiary failed to warn plaintiff of the risk of becoming addicted to cigarettes. | On August 23, 2016, our subsidiary filed its notice of appeal. On October 31, 2017, the Civil and Commercial Court of Appeals of Mar del Plata ruled that plaintiff's claim was barred by the statute of limitations and it reversed the trial court's decision. On November 28, 2017, plaintiff filed an extraordinary appeal of the reversal of the trial court's decision to the Supreme Court of the Province of Buenos Aires. |
• | 53 cases brought by individual plaintiffs in Argentina (32), Brazil (8), Canada (2), Chile (4), Costa Rica (1), Italy (1), the Philippines (1), Poland (2), Turkey (1) and Scotland (1), compared with 62 such cases on April 24, 2018, and 63 cases on April 25, 2017; and |
• | 10 cases brought on behalf of classes of individual plaintiffs in Brazil (1) and Canada (9), compared with 11 such cases on April 24, 2018 and 11 such cases on April 25, 2017. |
(in millions) | March 31, 2019 | December 31, 2018 | ||||||
U.S. dollar notes, 1.875% to 6.375% (average interest rate 3.499%), due through 2044 | $ | 18,879 | $ | 20,819 | ||||
Foreign currency obligations: | ||||||||
Euro notes, 0.625% to 3.125% (average interest rate 2.250%), due through 2037 | 8,498 | 8,656 | ||||||
Swiss franc notes, 0.750% to 2.000% (average interest rate 1.337%), due through 2024 | 1,155 | 1,374 | ||||||
Other (average interest rate 3.272%), due through 2024 | 181 | 180 | ||||||
28,713 | 31,029 | |||||||
Less current portion of long-term debt | 5,582 | 4,054 | ||||||
$ | 23,131 | $ | 26,975 |
Type | Committed Credit Facilities | |||
364-day revolving credit, expiring February 4, 2020 | $ | 2.0 | ||
Multi-year revolving credit, expiring February 28, 2021 | 2.5 | |||
Multi-year revolving credit, expiring October 1, 2022 | 3.5 | |||
Total facilities | $ | 8.0 |
Level 1 - | Quoted prices in active markets for identical assets or liabilities; |
Level 2 - | Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and |
Level 3 - | Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. |
(in millions) | Fair Value at March 31, 2019 | Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | ||||||||||||
Assets: | ||||||||||||||||
Equity securities | $ | 320 | $ | 320 | $ | — | $ | — | ||||||||
Derivative contracts | 359 | — | 359 | — | ||||||||||||
Total assets | $ | 679 | $ | 320 | $ | 359 | $ | — | ||||||||
Liabilities: | ||||||||||||||||
Debt | $ | 29,787 | $ | 29,626 | $ | 161 | $ | — | ||||||||
Derivative contracts | 566 | — | 566 | — | ||||||||||||
Total liabilities | $ | 30,353 | $ | 29,626 | $ | 727 | $ | — |
(in millions) | At March 31, 2019 | At December 31, 2018 | At March 31, 2018 | |||||||||
Currency translation adjustments | $ | (5,711 | ) | $ | (6,500 | ) | $ | (6,097 | ) | |||
Pension and other benefits | (3,556 | ) | (3,646 | ) | (2,766 | ) | ||||||
Derivatives accounted for as hedges | 30 | 35 | (20 | ) | ||||||||
Total accumulated other comprehensive losses | $ | (9,237 | ) | $ | (10,111 | ) | $ | (8,883 | ) |
(in millions) | Gross Amounts Recognized | Gross Amount Offset in the Condensed Consolidated Balance Sheet | Net Amounts Presented in the Condensed Consolidated Balance Sheet | Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet | |||||||||||||||
Financial Instruments | Cash Collateral Received/Pledged | Net Amount | |||||||||||||||||
At March 31, 2019 | |||||||||||||||||||
Assets | |||||||||||||||||||
Derivative contracts | $ | 359 | $ | — | $ | 359 | $ | (291 | ) | $ | (46 | ) | $ | 22 | |||||
Liabilities | |||||||||||||||||||
Derivative contracts | $ | 566 | $ | — | $ | 566 | $ | (291 | ) | $ | (268 | ) | $ | 7 | |||||
At December 31, 2018 | |||||||||||||||||||
Assets | |||||||||||||||||||
Derivative contracts | $ | 220 | $ | — | $ | 220 | $ | (124 | ) | $ | (80 | ) | $ | 16 | |||||
Liabilities | |||||||||||||||||||
Derivative contracts | $ | 631 | $ | — | $ | 631 | $ | (124 | ) | $ | (427 | ) | $ | 80 |
For the Three Months Ended March 31, | ||||||
(in millions) | 2019 | 2018 | ||||
Net revenues: | ||||||
Megapolis Group | $ | 359 | $ | 357 | ||
Other | 213 | 164 | ||||
Net revenues (a) | $ | 572 | $ | 521 |
(in millions) | At March 31, 2019 | At December 31, 2018 | |||||
Receivables: | |||||||
Megapolis Group | $ | 434 | $ | 172 | |||
Other | 150 | 136 | |||||
Receivables | $ | 584 | $ | 308 | |||
Payables: | |||||||
Megapolis Group | $ | 2 | $ | — | |||
Other | 57 | 8 | |||||
Payables | $ | 59 | $ | 8 |
For the Three Months Ended | For the Year Ended | |||||
(in millions) | March 31, 2019 | December 31, 2018 | ||||
Balance at beginning of period | $ | 67 | $ | 71 | ||
Changes due to: | ||||||
Warranties issued | 78 | 179 | ||||
Settlements | (39 | ) | (183 | ) | ||
Balance at end of period | $ | 106 | $ | 67 |
(in millions) | March 31, 2019 | ||
Assets: | |||
Other assets | $ | 707 | |
Liabilities: | |||
Current | |||
Accrued liabilities - Other | $ | 180 | |
Noncurrent | |||
Income taxes and other liabilities | 526 | ||
Total lease liabilities | $ | 706 |
(in millions) | March 31, 2019 | ||
Operating lease cost | $ | 60 | |
Short-term lease cost | 12 | ||
Variable lease cost | 8 | ||
Total lease cost | $ | 80 |
(in millions) | Total | ||
2019 | $ | 159 | |
2020 | 164 | ||
2021 | 120 | ||
2022 | 85 | ||
2023 | 63 | ||
Thereafter | 313 | ||
Total lease payments | 904 | ||
Less: Interest | 198 | ||
Present value of lease liabilities | $ | 706 |
(in millions) | Total | ||
2019 | $ | 147 | |
2020 | 103 | ||
2021 | 73 | ||
2022 | 52 | ||
2023 | 43 | ||
Thereafter | 354 | ||
$ | 772 |
(in millions) | March 31, 2019 | ||
Cash paid for amounts included in the measurement of lease liabilities in Operating cash flows | $ | 59 | |
Leased assets obtained in exchange for new operating lease liabilities | $ | 53 | |
Weighted-average remaining lease term (years) | 10.4 | ||
Weighted-average discount rate(1) | 4.7 | % |
• | European Union ("EU"); |
• | Eastern Europe ("EE"); |
• | Middle East & Africa ("ME&A"), which includes our international duty free business; |
• | South & Southeast Asia ("S&SA"); |
• | East Asia & Australia ("EA&A"); and |
• | Latin America & Canada ("LA&C"). |
• | Net Revenues - Net revenues of $6.8 billion for the three months ended March 31, 2019 decreased by $145 million, or (2.1)%, from the comparable 2018 amount. The change in our net revenues from the comparable 2018 amount was driven by the following: |
• | Diluted Earnings Per Share - The changes in our reported diluted earnings per share ("diluted EPS") for the three months ended March 31, 2019, from the comparable 2018 amounts, were as follows: |
Diluted EPS | % Growth (Decline) | ||||
For the three months ended March 31, 2018 | $ | 1.00 | |||
2018 Asset impairment and exit costs | — | ||||
2018 Tax items | — | ||||
Subtotal of 2018 items | — | ||||
2019 Asset impairment and exit costs | (0.01 | ) | |||
2019 Canadian tobacco litigation-related expense | (0.09 | ) | |||
2019 Loss on deconsolidation of RBH | (0.12 | ) | |||
2019 Tax items | — | ||||
Subtotal of 2019 items | (0.22 | ) | |||
Currency | (0.06 | ) | |||
Interest | 0.03 | ||||
Change in tax rate | 0.04 | ||||
Operations | 0.08 | ||||
For the three months ended March 31, 2019 | $ | 0.87 | (13.0 | )% |
• | European Union: Favorable volume/mix and favorable pricing, partially offset by higher manufacturing costs; |
• | South & Southeast Asia: Favorable pricing and favorable volume/mix, partially offset by higher marketing, administration and research costs and higher manufacturing costs; and |
• | Latin America & Canada: Favorable pricing, lower manufacturing costs and lower marketing, administration and research costs, partially offset by unfavorable volume/mix; |
• | East Asia & Australia: Unfavorable volume/mix, partially offset by favorable pricing and lower manufacturing costs; |
• | Middle East & Africa: Unfavorable pricing, partially offset by favorable volume/mix; and |
• | Eastern Europe: Higher marketing, administration and research costs and higher manufacturing costs, partially offset by favorable pricing and favorable volume/mix. |
(in millions) | For the Three Months Ended March 31, | |||||||
2019 | 2018 | Change | ||||||
Net revenues: | ||||||||
European Union | $ | 2,159 | $ | 1,988 | 8.6 | % | ||
Eastern Europe | 579 | 567 | 2.1 | % | ||||
Middle East & Africa | 927 | 961 | (3.5 | )% | ||||
South & Southeast Asia | 1,113 | 1,081 | 3.0 | % | ||||
East Asia & Australia | 1,321 | 1,591 | (17.0 | )% | ||||
Latin America & Canada | 652 | 708 | (7.9 | )% | ||||
Net revenues | $ | 6,751 | $ | 6,896 | (2.1 | )% | ||
Operating income (loss): | ||||||||
European Union | $ | 896 | $ | 740 | 21.1 | % | ||
Eastern Europe | 129 | 151 | (14.6 | )% | ||||
Middle East & Africa | 344 | 374 | (8.0 | )% | ||||
South & Southeast Asia | 440 | 429 | 2.6 | % | ||||
East Asia & Australia | 427 | 515 | (17.1 | )% | ||||
Latin America & Canada | (186 | ) | 217 | >(100)% | ||||
Operating income | $ | 2,050 | $ | 2,426 | (15.5 | )% |
• | Asset impairment and exit costs - See Note 19. Asset Impairment and Exit Costs for details of the $20 million pre-tax charge included in the South & Southeast Asia segment for the three months ended March 31, 2019. |
• | Canadian tobacco litigation-related expense - See Note 8. Contingencies and Note 20. Deconsolidation of RBH for details of the $194 million pre-tax charge included in the Latin America & Canada segment for the three months ended March 31, 2019. |
• | Loss on deconsolidation of RBH - See Note 20. Deconsolidation of RBH for details of the $239 million loss included in the Latin America & Canada segment for the three months ended March 31, 2019. |
PMI Net Revenues by Product Category | ||||||||
(in millions) | For the Three Months Ended March 31, | |||||||
2019 | 2018 | Change | ||||||
Combustible Products | ||||||||
European Union | $ | 1,812 | $ | 1,836 | (1.3 | )% | ||
Eastern Europe | 471 | 527 | (10.7 | )% | ||||
Middle East & Africa | 829 | 884 | (6.2 | )% | ||||
South & Southeast Asia | 1,113 | 1,081 | 3.0 | % | ||||
East Asia & Australia | 638 | 737 | (13.5 | )% | ||||
Latin America & Canada | 646 | 704 | (8.2 | )% | ||||
Total Combustible Products | $ | 5,508 | $ | 5,769 | (4.5 | )% | ||
Reduced-Risk Products | ||||||||
European Union | $ | 347 | $ | 152 | +100% | |||
Eastern Europe | 108 | 40 | +100% | |||||
Middle East & Africa | 98 | 77 | 27.2 | % | ||||
South & Southeast Asia | — | — | — | % | ||||
East Asia & Australia | 683 | 854 | (20.0 | )% | ||||
Latin America & Canada | 6 | 4 | 45.9 | % | ||||
Total Reduced-Risk Products | $ | 1,243 | $ | 1,127 | 10.3 | % | ||
Total PMI Net Revenues | $ | 6,751 | $ | 6,896 | (2.1 | )% |
PMI Shipment Volume (Million Units) | ||||||
For the Three Months Ended March 31, | ||||||
2019 | 2018 | Change | ||||
Cigarettes | ||||||
European Union | 39,488 | 39,671 | (0.5 | )% | ||
Eastern Europe | 20,320 | 22,039 | (7.8 | )% | ||
Middle East & Africa | 33,304 | 29,248 | 13.9 | % | ||
South & Southeast Asia | 41,492 | 40,218 | 3.2 | % | ||
East Asia & Australia | 12,113 | 14,091 | (14.0 | )% | ||
Latin America & Canada | 17,580 | 19,013 | (7.5 | )% | ||
Total Cigarettes | 164,297 | 164,280 | — | % | ||
Heated Tobacco Units | ||||||
European Union | 2,293 | 928 | +100% | |||
Eastern Europe | 1,548 | 564 | +100% | |||
Middle East & Africa | 754 | 709 | 6.3 | % | ||
South & Southeast Asia | — | — | — | % | ||
East Asia & Australia | 6,849 | 7,342 | (6.7 | )% | ||
Latin America & Canada | 54 | 23 | +100% | |||
Total Heated Tobacco Units | 11,498 | 9,566 | 20.2 | % | ||
Cigarettes and Heated Tobacco Units | ||||||
European Union | 41,781 | 40,599 | 2.9 | % | ||
Eastern Europe | 21,868 | 22,603 | (3.3 | )% | ||
Middle East & Africa | 34,058 | 29,957 | 13.7 | % | ||
South & Southeast Asia | 41,492 | 40,218 | 3.2 | % | ||
East Asia & Australia | 18,962 | 21,433 | (11.5 | )% | ||
Latin America & Canada | 17,634 | 19,036 | (7.4 | )% | ||
Total Cigarettes and Heated Tobacco Units | 175,795 | 173,846 | 1.1 | % |
For the Three Months Ended March 31, | ||||||||||||||||||
PMI Shipments (billion units) | PMI Market Share (%)(1) | |||||||||||||||||
Market | Total Market (billion units) | Total | Cigarette | Heated Tobacco Unit | Total | Heated Tobacco Unit | ||||||||||||
2019 | 2018 | 2019 | 2018 | 2019 | 2018 | 2019 | 2018 | 2019 | 2018 | 2019 | 2018 | |||||||
European Union | ||||||||||||||||||
France | 9.1 | 10.0 | 4.2 | 4.4 | 4.1 | 4.4 | — | — | 45.0 | 44.8 | 0.2 | 0.1 | ||||||
Germany | 15.4 | 16.1 | 6.1 | 5.8 | 5.9 | 5.8 | 0.2 | 0.1 | 39.5 | 36.3 | 1.0 | 0.4 | ||||||
Italy | 15.6 | 16.1 | 7.7 | 8.0 | 7.1 | 7.7 | 0.6 | 0.3 | 51.1 | 52.1 | 3.7 | 1.5 | ||||||
Poland | 10.6 | 9.8 | 4.2 | 3.9 | 4.0 | 3.9 | 0.2 | — | 39.9 | 39.7 | 1.8 | 0.5 | ||||||
Spain | 10.2 | 9.9 | 3.6 | 3.2 | 3.5 | 3.2 | 0.1 | — | 31.8 | 32.3 | 0.6 | 0.3 | ||||||
Eastern Europe | ||||||||||||||||||
Russia | 45.8 | 50.0 | 12.1 | 12.8 | 11.3 | 12.5 | 0.8 | 0.3 | 28.9 | 26.8 | 3.1 | 0.5 | ||||||
Middle East & Africa | ||||||||||||||||||
Saudi Arabia | 5.3 | 4.9 | 3.8 | 1.1 | 3.8 | 1.1 | — | — | 41.8 | 41.6 | — | — | ||||||
Turkey | 28.4 | 25.8 | 13.9 | 11.5 | 13.9 | 11.5 | — | — | 48.9 | 44.5 | — | — | ||||||
South & Southeast Asia | ||||||||||||||||||
Indonesia | 68.7 | 69.3 | 22.1 | 23.0 | 22.1 | 23.0 | — | — | 32.2 | 33.2 | — | — | ||||||
Philippines | 16.8 | 15.4 | 11.7 | 10.8 | 11.7 | 10.8 | — | — | 70.1 | 70.2 | — | — | ||||||
East Asia & Australia | ||||||||||||||||||
Australia | 3.1 | 2.9 | 0.8 | 0.8 | 0.8 | 0.8 | — | — | 24.4 | 28.7 | — | — | ||||||
Japan | 37.8 | 39.6 | 12.1 | 14.1 | 6.5 | 7.9 | 5.7 | 6.2 | 34.4 | 34.7 | 16.9 | 15.8 | ||||||
Korea | 15.6 | 15.8 | 3.6 | 4.0 | 2.5 | 2.9 | 1.2 | 1.2 | 23.3 | 25.5 | 7.3 | 7.3 | ||||||
Latin America & Canada | ||||||||||||||||||
Argentina | 8.3 | 9.1 | 6.1 | 6.8 | 6.1 | 6.8 | — | — | 73.2 | 74.8 | — | — | ||||||
Mexico | 7.4 | 7.6 | 4.7 | 4.9 | 4.7 | 4.9 | — | — | 64.1 | 63.5 | — | — | ||||||
(1) Market share estimates are calculated using IMS data Note: % change for Total Market and PMI shipments in the discussion below is computed based on millions of units |
• | the EU, reflecting higher heated tobacco unit shipment volume across the Region, and higher cigarette shipment volume in Germany, Poland and Spain, partly offset by lower cigarette shipment volume in France and Italy; |
• | Middle East & Africa, primarily reflecting higher cigarette shipment volume, notably Algeria, Egypt, Saudi Arabia and Turkey, partly offset by lower cigarette shipment volume in PMI Duty Free; and |
• | South & South East Asia, reflecting higher cigarette shipment volume, principally in Pakistan, the Philippines and Thailand, partly offset by Indonesia; |
• | Eastern Europe, reflecting lower cigarette shipment volume, principally in Russia, partly offset by higher heated tobacco unit shipment volume across the Region, notably Russia; |
• | East Asia & Australia, reflecting lower cigarette shipment volume, notably in Japan and Korea, and lower heated tobacco unit shipment volume in Japan; and |
• | Latin America & Canada, reflecting lower cigarette shipment volume, principally in Argentina and Venezuela. |
• | A net unfavorable impact of 1.3 billion heated tobacco units, mainly due to Japan and Russia; and |
• | A net favorable impact of approximately 0.3 billion cigarettes, mainly driven by Saudi Arabia, partly offset by Japan, North Africa and PMI Duty Free. |
PMI Shipment Volume by Brand (Million Units) | ||||||
First-Quarter | ||||||
2019 | 2018 | Change | ||||
Cigarettes | ||||||
Marlboro | 59,963 | 57,973 | 3.4 | % | ||
L&M | 21,816 | 19,225 | 13.5 | % | ||
Chesterfield | 14,298 | 13,875 | 3.1 | % | ||
Philip Morris | 10,723 | 10,659 | 0.6 | % | ||
Parliament | 8,830 | 8,460 | 4.4 | % | ||
Sampoerna A | 7,901 | 8,624 | (8.4 | )% | ||
Bond Street | 5,671 | 6,975 | (18.7 | )% | ||
Dji Sam Soe | 6,651 | 6,696 | (0.7 | )% | ||
Lark | 5,270 | 5,577 | (5.5 | )% | ||
Fortune | 3,045 | 3,583 | (15.0 | )% | ||
Others | 20,129 | 22,633 | (11.1 | )% | ||
Total Cigarettes | 164,297 | 164,280 | — | % | ||
Heated Tobacco Units | 11,498 | 9,566 | 20.2 | % | ||
Total Cigarettes and Heated Tobacco Units | 175,795 | 173,846 | 1.1 | % |
• | Marlboro, mainly driven by Algeria, Germany, Indonesia, the Philippines, Saudi Arabia, Spain and Turkey, partly offset by Argentina, Italy, Japan, PMI Duty Free and Russia; |
• | L&M, mainly driven by Egypt, Saudi Arabia and Thailand, partly offset by Russia; |
• | Chesterfield, mainly driven by Mexico, Saudi Arabia and Turkey, partly offset by Argentina, Italy and Venezuela; |
• | Philip Morris, mainly driven by Russia, partly offset by Argentina; and |
• | Parliament, mainly driven by Turkey, partly offset by Korea. |
• | Sampoerna A and Dji Sam Soe in Indonesia, mainly reflecting the impact of retail price increases resulting in widened price gaps with competitors' products and the impact of estimated trade inventory movements following the absence of an excise tax increase in January 2019; |
• | Bond Street, mainly due to Russia and Ukraine; |
• | Lark, mainly due to Japan, partly offset by Turkey; |
• | Fortune in the Philippines, mainly reflecting up-trading to Marlboro resulting from a narrowed price gap; and |
• | "Others," mainly due to: mid-price brands, notably Sampoerna U in Indonesia, partly reflecting the impact of above-inflation retail price increases; the successful portfolio consolidation of local, low-price brands into international trademarks, notably in Mexico and Russia. |
• | Total international cigarette market share of 26.4%, up by 0.5 points; and |
• | Total international heated tobacco unit market share of 2.0%, up by 0.5 points. |
Financial Summary | ||||||||||||||||||||||||||||
Financial Summary - Quarters Ended March 31, | Change Fav./(Unfav.) | Variance Fav./(Unfav.) | ||||||||||||||||||||||||||
2019 | 2018 | Total | Excl. Curr. | Total | Cur- rency | Price | Vol/ Mix | Cost/ Other | ||||||||||||||||||||
(in millions) | ||||||||||||||||||||||||||||
Net Revenues | $ | 6,751 | $ | 6,896 | (2.1 | )% | 3.2 | % | $ | (145 | ) | $ | (369 | ) | $ | 228 | $ | (15 | ) | $ | 11 | |||||||
Cost of Sales | (2,465 | ) | (2,615 | ) | 5.7 | % | 1.5 | % | 150 | 110 | — | 10 | 30 | |||||||||||||||
Marketing, Administration and Research Costs (1) | (2,217 | ) | (1,833 | ) | (20.9 | )% | (27.2 | )% | (384 | ) | 114 | — | — | (498 | ) | |||||||||||||
Amortization of Intangibles | (19 | ) | (22 | ) | 13.6 | % | 9.1 | % | 3 | 1 | — | — | 2 | |||||||||||||||
Operating Income | $ | 2,050 | $ | 2,426 | (15.5 | )% | (9.6 | )% | $ | (376 | ) | $ | (144 | ) | $ | 228 | $ | (5 | ) | $ | (455 | ) |
• | regulatory restrictions on our products, including restrictions on the packaging, marketing, and sale of tobacco or other nicotine-containing products that could reduce our competitiveness, eliminate our ability to communicate with adult consumers, or even ban certain of our products; |
• | fiscal challenges, such as excessive excise tax increases and discriminatory tax structures; |
• | illicit trade in cigarettes and other tobacco products, including counterfeit, contraband and so-called “illicit whites”; |
• | intense competition, including from non-tax paid volume by certain local manufacturers; |
• | pending and threatened litigation as discussed in Note 8. Contingencies; and |
• | governmental investigations. |
• | health warnings covering 65% of the front and back panels of cigarette packs, with an option for Member States to further standardize tobacco packaging, including the introduction of plain packaging; |
• | a ban on characterizing flavors in some tobacco products, with a transition period for menthol expiring in May 2020; |
• | security features and tracking and tracing measures that will become effective on May 20, 2019, and will increase our operating expenses; and |
• | a framework for the regulation of novel tobacco products and e-cigarettes, including requirements for health warnings and information leaflets, a prohibition on product packaging text related to reduced risk, and the introduction of notification requirements or authorization procedures in advance of commercialization. |
• | to develop RRPs that adult smokers who would otherwise continue to smoke find to be satisfying alternatives to smoking; |
• | for those adult smokers, our goal is to offer RRPs with a scientifically substantiated risk-reduction profile that approaches as closely as possible that associated with smoking cessation; |
• | to substantiate the reduction of risk for the individual adult smoker and the reduction of harm to the population as a whole, based on scientific evidence of the highest standard that is made available for scrutiny and review by external independent scientists and relevant regulatory bodies; and |
• | to advocate for the development of science-based regulatory frameworks for the development and commercialization of RRPs, including the communication of scientifically substantiated information to enable adult smokers to make better consumer choices. |
• | We currently market our e-vapor products in Ireland and the U.K. In July 2018, we pilot-launched IQOS MESH, one of our Platform 4 products, in London, U.K. |
• | We completed a small-scale city test of TEEPS, our Platform 2 product, that we had initiated in December 2017 in Santo Domingo, the Dominican Republic, and are working on improving this product and incorporating our learnings into our future plans. |
• | Depending on the outcome of the use and adaptation study described above, we plan to conduct a consumer test of our Platform 3 product. |
Financial Summary - Quarters Ended March 31, | Change Fav./(Unfav.) | Variance Fav./(Unfav.) | ||||||||||||||||||||||||||
2019 | 2018 | Total | Excl. Curr. | Total | Cur- rency | Price | Vol/ Mix | Cost/ Other | ||||||||||||||||||||
(in millions) | ||||||||||||||||||||||||||||
Net Revenues | $ | 2,159 | $ | 1,988 | 8.6 | % | 15.8 | % | $ | 171 | $ | (143 | ) | $ | 68 | $ | 246 | $ | — | |||||||||
Operating Income | $ | 896 | $ | 740 | 21.1 | % | 31.1 | % | $ | 156 | $ | (74 | ) | $ | 68 | $ | 197 | $ | (35 | ) |
European Union Key Data | First-Quarter | ||||||
Change | |||||||
2019 | 2018 | % / pp | |||||
Total Market (billion units) | 107.3 | 107.8 | (0.5 | )% | |||
PMI Shipment Volume (million units) | |||||||
Cigarettes | 39,488 | 39,671 | (0.5 | )% | |||
Heated Tobacco Units | 2,293 | 928 | +100.0% | ||||
Total European Union | 41,781 | 40,599 | 2.9 | % | |||
PMI Market Share | |||||||
Marlboro | 18.2 | % | 18.3 | % | (0.1 | ) | |
L&M | 6.7 | % | 6.7 | % | — | ||
Chesterfield | 5.9 | % | 5.9 | % | — | ||
Philip Morris | 2.8 | % | 3.1 | % | (0.3 | ) | |
HEETS | 2.1 | % | 0.8 | % | 1.3 | ||
Others | 3.2 | % | 3.4 | % | (0.2 | ) | |
Total European Union | 38.9 | % | 38.2 | % | 0.7 |
• | France, down by 8.1%, mainly due to the impact of significant excise-tax driven price increases in March 2018 and 2019, as well as an increase in the prevalence of illicit trade; |
• | Germany, down by 4.0%, or by 1.0% excluding the net impact of estimated trade inventory movements of competitors' products in the quarter, primarily reflecting the impact of price increases in March 2018; and |
• | Italy, down by 2.9%, or by 1.7% excluding the net impact of estimated trade inventory movements, primarily reflecting the impact of price increases in 2018 and in February 2019; |
• | Poland, up by 8.1%, primarily reflecting a lower prevalence of illicit trade; and |
• | Spain, up by 2.7%, partly reflecting a lower prevalence of illicit trade. |
• | higher heated tobacco unit shipment volume across the Region, notably Italy, driven by higher market share; and |
• | higher cigarette shipment volume in: Germany, primarily reflecting higher market share of cigarettes, particularly of Marlboro, benefiting from estimated favorable trade inventory movements in the quarter noted above; Poland, mainly driven by a higher total market; and Spain, primarily reflecting net favorable estimated distributor movements; |
• | lower cigarette shipment volume, notably in France, mainly reflecting a lower total market, and Italy, primarily reflecting the lower total market, due mainly to the impact of price increases in March 2018 and February 2019, as well as lower cigarette market share due to out-switching to HEETS. |
Financial Summary - Quarters Ended March 31, | Change Fav./(Unfav.) | Variance Fav./(Unfav.) | ||||||||||||||||||||||||||
2019 | 2018 | Total | Excl. Curr. | Total | Cur- rency | Price | Vol/ Mix | Cost/ Other | ||||||||||||||||||||
(in millions) | ||||||||||||||||||||||||||||
Net Revenues | $ | 579 | $ | 567 | 2.1 | % | 13.4 | % | $ | 12 | $ | (64 | ) | $ | 17 | $ | 59 | $ | — | |||||||||
Operating Income | $ | 129 | $ | 151 | (14.6 | )% | (2.0 | )% | $ | (22 | ) | $ | (19 | ) | $ | 17 | $ | 14 | $ | (34 | ) |
• | Russia, down by 8.3%, primarily reflecting the impact of price increases, as well as the unfavorable impact in the quarter of estimated trade inventory movements in certain key accounts; and |
• | Ukraine, down by 10.6%, primarily reflecting the impact of price increases and an increase in the prevalence of illicit trade. |
PMI Shipment Volume (million units) | First-Quarter | |||||
2019 | 2018 | Change | ||||
Cigarettes | 20,320 | 22,039 | (7.8 | )% | ||
Heated Tobacco Units | 1,548 | 564 | +100.0% | |||
Total Eastern Europe | 21,868 | 22,603 | (3.3 | )% |
• | Russia, down by 5.0%. Excluding the net unfavorable impact of estimated distributor inventory movements of 0.5 billion units, primarily of heated tobacco units, reflecting an adjustment subsequent to the increase in shipments in the fourth quarter of 2018 ahead of their planned geographic expansion, our in-market sales decline was 0.9%, reflecting a lower total market, partly offset by higher market share of heated tobacco units; |
• | Kazakhstan, up by 12.3%, reflecting a higher total market and a higher market share of heated tobacco units; and |
• | Ukraine, up by 2.3%, reflecting a higher market share of cigarettes and heated tobacco units, partly offset by a lower total market. |
Financial Summary - Quarters Ended March 31, | Change Fav./(Unfav.) | Variance Fav./(Unfav.) | ||||||||||||||||||||||||||
2019 | 2018 | Total | Excl. Curr. | Total | Cur- rency | Price | Vol/ Mix | Cost/ Other | ||||||||||||||||||||
(in millions) | ||||||||||||||||||||||||||||
Net Revenues | $ | 927 | $ | 961 | (3.5 | )% | 3.5 | % | $ | (34 | ) | $ | (68 | ) | $ | (50 | ) | $ | 73 | $ | 11 | |||||||
Operating Income | $ | 344 | $ | 374 | (8.0 | )% | (1.1 | )% | $ | (30 | ) | $ | (26 | ) | $ | (50 | ) | $ | 35 | $ | 11 |
• | Algeria, up by 19.3%, or down by 0.8% excluding the net favorable impact of estimated trade inventory movements associated with expectations regarding excise tax announcements in 2019 compared to 2018; |
• | Saudi Arabia, up by 8.1%, primarily reflecting a favorable comparison with the first quarter of 2018, which was down by 40.8% mainly due to the impact of retail price increases in 2017 and the first quarter of 2018 following the introduction of the new excise tax in June 2017 and VAT in January 2018; and |
• | Turkey, up by 10.1%, or by 4.3%, excluding the net favorable impact of estimated trade inventory movements associated with expectations regarding excise tax and pricing changes in 2019 compared to 2018 following the excise tax increase in January 2019. |
PMI Shipment Volume (million units) | First-Quarter | |||||
2019 | 2018 | Change | ||||
Cigarettes | 33,304 | 29,248 | 13.9 | % | ||
Heated Tobacco Units | 754 | 709 | 6.3 | % | ||
Total Middle East & Africa | 34,058 | 29,957 | 13.7 | % |
• | North Africa, notably in: Algeria, up by 36.4%, reflecting a higher total market, as well as higher market share benefiting from the estimated trade inventory movements noted above; and Egypt, up by 9.4%, primarily reflecting higher market share, driven by L&M; |
• | Saudi Arabia, up by +100%. Net favorable estimated distributor inventory movements in the quarter totaled 2.6 billion cigarettes, mainly attributable to: adjustments ahead of an importation deadline before the implementation of plain packaging scheduled for January 1, 2020; port closures related to the timing of Ramadan; and adjustments in 2018 following the introduction of the new excise tax in 2017. Excluding the impact of these inventory movements, our in-market sales grew by 8.6%, reflecting a favorable comparison with the first quarter of 2018, which was down by 54.5%, mainly due to the impact of the factors described for the total market above; and |
• | Turkey, up by 21.1%, reflecting a higher total market and a higher market share, notably of Marlboro and Parliament; |
• | PMI Duty Free, down by 12.4%. Excluding the net unfavorable impact of estimated distributor inventory movements of 0.5 billion units, principally cigarettes, our in-market sales decline was 3.1%, notably reflecting the retail travel industry decline in Asia. |
Financial Summary - Quarters Ended March 31, | Change Fav./(Unfav.) | Variance Fav./(Unfav.) | ||||||||||||||||||||||||||
2019 | 2018 | Total | Excl. Curr. | Total | Cur- rency | Price | Vol/ Mix | Cost/ Other | ||||||||||||||||||||
(in millions) | ||||||||||||||||||||||||||||
Net Revenues | $ | 1,113 | $ | 1,081 | 3.0 | % | 8.6 | % | $ | 32 | $ | (61 | ) | $ | 76 | $ | 17 | $ | — | |||||||||
Operating Income | $ | 440 | $ | 429 | 2.6 | % | 9.6 | % | $ | 11 | $ | (30 | ) | $ | 76 | $ | 14 | $ | (49 | ) |
• | Indonesia, down by 0.8%, mainly due to the impact of estimated trade inventory movements in the quarter following the absence of an excise tax increase in January 2019; |
• | Vietnam, down by 5.6% reflecting the unfavorable impact of trade inventory movements related to an anticipated excise tax increase in January 2019; |
• | the Philippines, up by 8.9%, benefiting from the net impact of favorable trade inventory movements associated with expectations regarding excise tax-driven price increases; and |
• | Thailand, up by 27.4%, primarily reflecting on-going recovery from the September 2017 excise tax reform. |
PMI Shipment Volume (million units) | First-Quarter | |||||
2019 | 2018 | Change | ||||
Cigarettes | 41,492 | 40,218 | 3.2 | % | ||
Heated Tobacco Units | — | — | — | % | ||
Total South & Southeast Asia | 41,492 | 40,218 | 3.2 | % |
• | Pakistan, up by 10.5%, mainly reflecting higher market share benefiting from estimated trade inventory movements in anticipation of excise tax-driven price increases in the first quarter of 2019; |
• | the Philippines, up by 8.8%, mainly reflecting the estimated trade inventory movements described above; and |
• | Thailand, up by 33.3%, mainly reflecting a higher total market, as well as a higher market share driven by the continued strong performance of L&M 7.1 and the favorable impact of distribution expansion in 2018; |
• | Indonesia, down by 3.7%, mainly reflecting a lower market share primarily due to the widened retail price gap of A Mild to competitive brands following its price increase in October 2018, as well as the lower total market. |
Financial Summary - Quarters Ended March 31, | Change Fav./(Unfav.) | Variance Fav./(Unfav.) | ||||||||||||||||||||||
2019 | 2018 | Total | Excl. Curr. | Total | Cur- rency | Price | Vol/ Mix | Cost/ Other | ||||||||||||||||
(in millions) | ||||||||||||||||||||||||
Net Revenues | $ 1,321 | $ 1,591 | (17.0 | )% | (17.0 | )% | $ | (270 | ) | $ | — | $ | 86 | $ | (356 | ) | $ | — | ||||||
Operating Income | $ 427 | $ 515 | (17.1 | )% | (16.1 | )% | $ | (88 | ) | $ | (5 | ) | $ | 86 | $ | (222 | ) | $ | 53 |
• | Japan, down by 4.5%, mainly reflecting the impact of the October 1, 2018 excise tax-driven retail price increases; |
• | Taiwan, up by 16.6%, primarily driven by a favorable comparison with the first quarter of 2018 that was down by 23.9% reflecting the impact of excise tax-driven price increases in 2017. |
PMI Shipment Volume (million units) | First-Quarter | |||||
2019 | 2018 | Change | ||||
Cigarettes | 12,113 | 14,091 | (14.0 | )% | ||
Heated Tobacco Units | 6,849 | 7,342 | (6.7 | )% | ||
Total East Asia & Australia | 18,962 | 21,433 | (11.5 | )% |
• | Japan, down by 14.2%. Excluding the net unfavorable impact of estimated distributor inventory movements of approximately 1.2 billion units, comprised of approximately 0.7 billion heated tobacco units and approximately 0.5 billion cigarettes, our in-market sales decline was 5.6%, reflecting the lower total market and lower cigarette market share; and |
• | Korea, down by 9.7%, principally due to lower cigarette market share, notably of Marlboro and Parliament. |
Financial Summary - Quarters Ended March 31, | Change Fav./(Unfav.) | Variance Fav./(Unfav.) | ||||||||||||||||||||||||||
2019 | 2018 | Total | Excl. Curr. | Total | Cur- rency | Price | Vol/ Mix | Cost/ Other | ||||||||||||||||||||
(in millions) | ||||||||||||||||||||||||||||
Net Revenues | $ | 652 | $ | 708 | (7.9 | )% | (3.2 | )% | $ | (56 | ) | $ | (33 | ) | $ | 31 | $ | (54 | ) | $ | — | |||||||
Operating Income (Loss) | $ | (186 | ) | $ | 217 | -(100)% | -(100)% | $ | (403 | ) | $ | 10 | $ | 31 | $ | (43 | ) | $ | (401 | ) |
• | Argentina, down by 9.1%, primarily due to the impact of cumulative price increases and the continuing economic downturn; |
• | Brazil, down by 5.2%, mainly due to the impact of cumulative price increases; |
• | Canada, down by 9.7%, primarily due to the impact of cumulative pricing; and |
• | Venezuela, down by 56.7%, mainly reflecting the deterioration of the socioeconomic environment and the impact of inflation-driven price increases. |
PMI Shipment Volume (million units) | First-Quarter | |||||
2019 | 2018 | Change | ||||
Cigarettes | 17,580 | 19,013 | (7.5 | )% | ||
Heated Tobacco Units | 54 | 23 | +100.0% | |||
Total Latin America & Canada | 17,634 | 19,036 | (7.4 | )% |
• | Argentina, down by 11.0%, primarily reflecting the lower total market; and |
• | Canada, down by 8.2%, reflecting the lower total market; |
• | Brazil, up by 1.9%, reflecting higher market share, up by 1.5 points to 20.6%, mainly driven by Chesterfield, partly offset by a lower total market. |
Short-term | Long-term | Outlook | ||||
Moody’s | P-1 | A2 | Stable | |||
Standard & Poor’s | A-1 | A | Stable | |||
Fitch | F1 | A | Stable |
(in billions) | ||||||||
Type | Committed Credit Facilities | Commercial Paper | ||||||
364-day revolving credit, expiring February 4, 2020 | $ | 2.0 | ||||||
Multi-year revolving credit, expiring February 28, 2021 | 2.5 | |||||||
Multi-year revolving credit, expiring October 1, 2022 | 3.5 | |||||||
Total facilities | $ | 8.0 | ||||||
Commercial paper outstanding | $ | 1.0 |
• | restrictions on or licensing of outlets permitted to sell cigarettes; |
• | the levying of substantial and increasing tax and duty charges; |
• | restrictions or bans on advertising, marketing and sponsorship; |
• | the display of larger health warnings, graphic health warnings and other labeling requirements; |
• | restrictions on packaging design, including the use of colors, and plain packaging; |
• | restrictions on packaging and cigarette formats and dimensions; |
• | restrictions or bans on the display of tobacco product packaging at the point of sale and restrictions or bans on cigarette vending machines; |
• | requirements regarding testing, disclosure and performance standards for tar, nicotine, carbon monoxide and other smoke constituents; |
• | disclosure, restrictions, or bans of tobacco product ingredients; |
• | increased restrictions on smoking in public and work places and, in some instances, in private places and outdoors; |
• | regulation, restrictions or prohibitions of novel tobacco or nicotine-containing products; |
• | elimination of duty free sales and duty free allowances for travelers; |
• | encouraging litigation against tobacco companies; and |
• | excluding tobacco companies from transparent public dialogue regarding public health and other policy matters. |
• | promote brand equity successfully; |
• | anticipate and respond to new adult consumer trends; |
• | develop new products and markets and broaden brand portfolios; |
• | improve productivity; |
• | convince adult smokers to convert to our RRPs; |
• | ensure adequate production capacity to meet demand for our products; and |
• | be able to protect or enhance margins through price increases. |
Item 1. | Legal Proceedings. |
Item 1A. | Risk Factors. |
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds. |
Period | Total Number of Shares Repurchased | Average Price Paid Per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Approximate Dollar Value of Shares that May Yet be Purchased Under the Plans or Programs | ||||||||||
January 1, 2019 – January 31, 2019 (1) | — | $ | — | — | $ | — | ||||||||
February 1, 2019 – February 28, 2019 (1) | — | $ | — | — | $ | — | ||||||||
March 1, 2019 – March 31, 2019 (1) | — | $ | — | — | $ | — | ||||||||
Pursuant to Publicly Announced Plans or Programs | — | $ | — | |||||||||||
January 1, 2019 – January 31, 2019 (2) | 1,536 | $ | 66.98 | |||||||||||
February 1, 2019 – February 28, 2019 (2) | 130,536 | $ | 84.49 | |||||||||||
March 1, 2019 – March 31, 2019 (2) | 4,565 | $ | 87.15 | |||||||||||
For the Quarter Ended March 31, 2019 | 136,637 | $ | 84.38 |
(1) | During this reporting period, we did not have an authorized share repurchase program. |
(2) | Shares repurchased represent shares tendered to us by employees who vested in restricted and performance share unit awards and used shares to pay all, or a portion of, the related taxes. |
Item 6. | Exhibits. |
3.1 | ||
10.1 | ||
10.2 | ||
10.3 | ||
10.4 | ||
31.1 | ||
31.2 | ||
32.1 | ||
32.2 | ||
101.INS | XBRL Instance Document. | |
101.SCH | XBRL Taxonomy Extension Schema. | |
101.CAL | XBRL Taxonomy Extension Calculation Linkbase. | |
101.DEF | XBRL Taxonomy Extension Definition Linkbase. | |
101.LAB | XBRL Taxonomy Extension Label Linkbase. | |
101.PRE | XBRL Taxonomy Extension Presentation Linkbase. |
PHILIP MORRIS INTERNATIONAL INC. |
/s/ MARTIN G. KING |
Martin G. King |
Chief Financial Officer |
April 25, 2019 |
Page No | |||
ARTICLE I | DEFINITIONS | 2 | |
ARTICLE II | BENEFIT EQUALIZATION RETIREMENT ALLOWANCES AND BENEFIT EQUALIZATION PROFIT-SHARING ALLOWANCES | 13 | |
ARTICLE III | FUNDS FROM WHICH ALLOWANCES ARE PAYABLE | 21 | |
ARTICLE IV | THE ADMINISTRATOR | 22 | |
ARTICLE V | AMENDMENT AND DISCONTINUANCE OF THE PLAN | 23 | |
ARTICLE VI | FORMS; COMMUNICATIONS | 24 | |
ARTICLE VII | INTERPRETATION OF PROVISIONS | 25 | |
ARTICLE VIII | CHANGE IN CONTROL PROVISIONS | 26 |
A. | Benefit Equalization Retirement Allowances and other benefits payable under this Plan shall be as follows: |
B. | Benefit Equalization Profit-Sharing Allowances payable under this Plan shall be as follows: |
C. | BEP Benefit Commencement Date and termination of Benefit Equalization Retirement Allowances payable in the form of an Optional Payment: |
1. | I have reviewed this quarterly report on Form 10-Q of Philip Morris International Inc.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c. | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d. | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
/s/ ANDRÉ CALANTZOPOULOS |
André Calantzopoulos |
Chief Executive Officer |
1. | I have reviewed this quarterly report on Form 10-Q of Philip Morris International Inc.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c. | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d. | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
/s/ MARTIN G. KING |
Martin G. King |
Chief Financial Officer |
/s/ ANDRÉ CALANTZOPOULOS |
André Calantzopoulos |
Chief Executive Officer |
April 25, 2019 |
/s/ MARTIN G. KING |
Martin G. King |
Chief Financial Officer |
April 25, 2019 |
!/'?AGPCXG33+O
MXE>&?BA\4+;]H?P3^TWJD'A^^\,>')-4\+V'PZAOYOBM!IVF^)OAOJW]J? [
M7E^)T6I:FGZHM\:O#^B?!&?X[?$O0_$7P8\.Z3X)NO'7BO0/BG+X3T3Q1X(T
M^QLYKR[T_P 5MI/BK7_"=CK$,<2PO#:>+-0L?M%Q;V_]HF1V">)6/[;7@X^"
MOA_XF\3_ E^-W@?Q7\3K/XAZ]X1^$&NZ!X$UOXH:EX&^%FE6NN^,_B-%9?#
MSXC>-_!]QX)TW2M3T.ZLK^P\:7NHZY<^)/#.C:%I6H:]XDT?2[L _.W]F?3_
M -J'X9>"_P!CG2KB#]H;Q@]KKLGA3XS_ P^)]S^T)H7CK1]9O\ ]H77])\1
M?%;2/BOJ5MK?P\\?Z'X=\-VXUCQE\-OB_+!H/BCX3VL7C+X)>.K+Q/K"V7C+
M]XP,@9&< =>3D=^0#GOG /L#Q7R)I?[;?P'\0^*/#F@>%=6U?Q9HWB2^^#^E
M6OCWP[IUM?\ @VSU?X^^%%\!S3KQGU*#Q0Z>._"]QIVL:9K.G>%M0\-:=;
MZI9C7=:TF6.^2Q^NP0P# Y# $'U!&0>>>GK0!XA\8OV:O@!^T!I[:;\:?@[\
M._B9!Y*P17'B[PMI6J:I9Q(S,HT[7)+==;TPH7
Document and Entity Information - shares |
3 Months Ended | |
---|---|---|
Mar. 31, 2019 |
Apr. 22, 2019 |
|
Document And Entity Information [Abstract] | ||
Entity Registrant Name | Philip Morris International Inc. | |
Entity Central Index Key | 0001413329 | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Large Accelerated Filer | |
Document Type | 10-Q | |
Document Period End Date | Mar. 31, 2019 | |
Document Fiscal Year Focus | 2019 | |
Document Fiscal Period Focus | Q1 | |
Amendment Flag | false | |
Entity Emerging Growth Company | false | |
Entity Small Business | false | |
Entity Common Stock, Shares Outstanding | 1,555,802,811 |
Condensed Consolidated Statements of Earnings - USD ($) $ in Millions |
3 Months Ended | |
---|---|---|
Mar. 31, 2019 |
Mar. 31, 2018 |
|
Income Statement [Abstract] | ||
Revenues including excise taxes | $ 17,705 | $ 18,426 |
Excise taxes on products | 10,954 | 11,530 |
Net revenues | 6,751 | 6,896 |
Cost of sales | 2,465 | 2,615 |
Gross profit | 4,286 | 4,281 |
Marketing, administration and research costs (Notes 19 & 20) | 2,217 | 1,833 |
Amortization of intangibles | 19 | 22 |
Operating income | 2,050 | 2,426 |
Interest expense, net | 152 | 227 |
Pension and other employee benefit costs (Note 3) | 21 | 6 |
Earnings before income taxes | 1,877 | 2,193 |
Provision for income taxes | 424 | 559 |
Equity investments and securities (income)/loss, net | (11) | (13) |
Net earnings | 1,464 | 1,647 |
Net earnings attributable to noncontrolling interests | 110 | 91 |
Net earnings attributable to PMI | $ 1,354 | $ 1,556 |
Per share data: | ||
Basic earnings per share (in dollars per share) | $ 0.87 | $ 1.00 |
Diluted earnings per share (in dollars per share) | $ 0.87 | $ 1.00 |
Condensed Consolidated Statements of Comprehensive Earnings (Parenthetical) - USD ($) $ in Millions |
3 Months Ended | |
---|---|---|
Mar. 31, 2019 |
Mar. 31, 2018 |
|
Income taxes on currency translation adjustments | $ (128) | $ 192 |
Income taxes on losses transferred to earnings - deconsolidation of RBH | 0 | 0 |
Income taxes on amortization of net losses, prior service costs and net transition costs And Losses transfered to earnings - deconsolidation of RBH | (4) | (11) |
Income taxes on (loss)/gain recognized from fair value of derivatives accounted for as hedges | 1 | 10 |
Income taxes on loss/(gain) transferred to earnings from fair value of derivatives accounted for as hedges | 1 | (1) |
Deconsolidation of RBH [Member] | ||
Income taxes on amortization of net losses, prior service costs and net transition costs And Losses transfered to earnings - deconsolidation of RBH | $ (15) | $ 0 |
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions |
Mar. 31, 2019 |
Dec. 31, 2018 |
---|---|---|
Statement of Financial Position [Abstract] | ||
Receivables, allowances | $ 25 | $ 25 |
Common stock, no par value (in dollars per share) | ||
Common stock, shares issued (in shares) | 2,109,316,331 | 2,109,316,331 |
Repurchased stock, shares (in shares) | 553,520,033 | 554,736,610 |
Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions |
3 Months Ended | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 |
Mar. 31, 2018 |
|||||||||
CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES | ||||||||||
Net earnings | $ 1,464 | $ 1,647 | ||||||||
Adjustments to reconcile net earnings to operating cash flows: | ||||||||||
Depreciation and amortization | 240 | 242 | ||||||||
Deferred income tax (benefit) provision | (94) | 26 | ||||||||
Cash effects of changes in: | ||||||||||
Receivables, net | 4 | (113) | ||||||||
Inventories | 237 | 338 | ||||||||
Accounts payable | (7) | (62) | ||||||||
Accrued liabilities and other current assets | (855) | (509) | ||||||||
Income taxes | (251) | (315) | ||||||||
Pension plan contributions | (17) | (25) | ||||||||
Other | 520 | [1] | 151 | |||||||
Net cash provided by operating activities | 1,241 | 1,380 | ||||||||
CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES | ||||||||||
Capital expenditures | (324) | (365) | ||||||||
Investments in unconsolidated subsidiaries and equity securities | (24) | (18) | ||||||||
Deconsolidation of RBH (Note 20) | (1,346) | [2] | 0 | |||||||
Net investment hedges | 91 | |||||||||
Net investment hedges | (665) | |||||||||
Other | 7 | 30 | ||||||||
Net cash used in investing activities | (1,596) | (1,018) | ||||||||
Short-term borrowing activity by original maturity: | ||||||||||
Net issuances - maturities of 90 days or less | (167) | 103 | ||||||||
Issuances - maturities longer than 90 days | 989 | 0 | ||||||||
Long-term debt repaid | (2,137) | 0 | ||||||||
Dividends paid | (1,780) | (1,659) | ||||||||
Sale (purchase) of subsidiary shares to/(from) noncontrolling interests (Note 17) | 0 | (91) | ||||||||
Other | (56) | (91) | ||||||||
Net cash used in financing activities | (3,151) | (1,738) | ||||||||
Effect of exchange rate changes on cash, cash equivalents and restricted cash | (28) | 131 | ||||||||
Cash, cash equivalents and restricted cash: | ||||||||||
Increase (Decrease) | [3] | (3,534) | (1,245) | |||||||
Balance at beginning of period | [3] | 6,620 | 8,476 | |||||||
Balance at end of period | [3] | $ 3,086 | $ 7,231 | |||||||
|
Condensed Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Millions |
3 Months Ended | |||
---|---|---|---|---|
Mar. 31, 2019 |
Dec. 31, 2018 |
Mar. 31, 2018 |
Dec. 31, 2017 |
|
Pre-tax asset impairment and exit costs | $ 20 | |||
Restricted cash | 5 | $ 27 | $ 31 | $ 29 |
Marketing Administration And Research Costs [Member] | ||||
Deconsolidation amount | 239 | |||
Cecilia Letourneau & Conseil Quebecois Sur La Tabac Et La Sante and Jean-Yves Blais Cases [Member] | RBH [Member] | Appellate Ruling [Member] | Smoking And Health Class Actions [Member] | ||||
Amount of litigation charge | 194 | |||
Canada [Member] | Cecilia Letourneau & Conseil Quebecois Sur La Tabac Et La Sante and Jean-Yves Blais Cases [Member] | RBH [Member] | Appellate Ruling [Member] | Smoking And Health Class Actions [Member] | ||||
Amount of litigation charge | 194 | |||
Deconsolidation of RBH [Member] | ||||
Restricted cash | 23 | |||
Cash [Member] | RBH [Member] | ||||
Amount deconsolidated from balance sheet | $ 1,323 |
Condensed Consolidated Statements of Stockholders' (Deficit) Equity - USD ($) $ in Millions |
Total |
Common Stock [Member] |
Additional Paid-in Capital [Member] |
Earnings Reinvested in the Business [Member] |
Accumulated Other Comprehensive Losses [Member] |
Cost of Repurchased Stock [Member] |
Noncontrolling Interests [Member] |
---|---|---|---|---|---|---|---|
Beginning balance at Dec. 31, 2017 | $ (10,230) | $ 0 | $ 1,972 | $ 29,859 | $ (8,535) | $ (35,382) | $ 1,856 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Net earnings | 1,647 | 1,556 | 91 | ||||
Other comprehensive earnings (losses), net of income taxes | (383) | (344) | (39) | ||||
Issuance of stock awards | 45 | (29) | 74 | ||||
Dividends declared | (1,668) | (1,668) | |||||
Payments to noncontrolling interests | (36) | (36) | |||||
Adoption of new accounting standards | 238 | 238 | |||||
Other (Note 17) | (95) | (87) | (4) | (4) | |||
Ending balance at Mar. 31, 2018 | (10,482) | 0 | 1,856 | 29,985 | (8,883) | (35,308) | 1,868 |
Beginning balance at Dec. 31, 2018 | (10,739) | 0 | 1,939 | 31,014 | (10,111) | (35,301) | 1,720 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Net earnings | 1,464 | 1,354 | 110 | ||||
Other comprehensive earnings (losses), net of income taxes | 873 | ||||||
Other comprehensive earnings (losses), excluding deconsolidation entity, net of taxes | 344 | 345 | (1) | ||||
Issuance of stock awards | 43 | (32) | 75 | ||||
Dividends declared | (1,780) | (1,780) | |||||
Payments to noncontrolling interests | (46) | (46) | |||||
Deconsolidation of RBH (Note 20) | 529 | 529 | |||||
Ending balance at Mar. 31, 2019 | $ (10,185) | $ 0 | $ 1,907 | $ 30,588 | $ (9,237) | $ (35,226) | $ 1,783 |
Condensed Consolidated Statements of Stockholders' (Deficit) Equity (Parenthetical) - $ / shares |
3 Months Ended | |
---|---|---|
Mar. 31, 2019 |
Mar. 31, 2018 |
|
Statement of Stockholders' Equity [Abstract] | ||
Dividends declared (in dollars per share) | $ 1.14 | $ 1.07 |
Background and Basis of Presentation |
3 Months Ended |
---|---|
Mar. 31, 2019 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Background and Basis of Presentation | Background and Basis of Presentation: Background Philip Morris International Inc. is a holding company incorporated in Virginia, U.S.A., whose subsidiaries and affiliates and their licensees are engaged in the manufacture and sale of cigarettes and other nicotine-containing products, including reduced-risk products, in markets outside of the United States of America. Throughout these financial statements, the term "PMI" refers to Philip Morris International Inc. and its subsidiaries. Reduced-risk products ("RRPs") is the term PMI uses to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continued smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Basis of Presentation The interim condensed consolidated financial statements of PMI are unaudited. These interim condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America and such principles are applied on a consistent basis. It is the opinion of PMI’s management that all adjustments necessary for a fair statement of the interim results presented have been reflected therein. All such adjustments were of a normal recurring nature. Net revenues and net earnings attributable to PMI for any interim period are not necessarily indicative of results that may be expected for the entire year. As of March 22, 2019, PMI deconsolidated the financial results of its Canadian subsidiary, Rothmans, Benson & Hedges Inc. ("RBH") from PMI's financial statements. For further details, see Note 20. Deconsolidation of RBH. These statements should be read in conjunction with the audited consolidated financial statements and related notes, which appear in PMI’s Annual Report on Form 10-K for the year ended December 31, 2018. |
Stock Plans |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Plans | Stock Plans: In May 2017, PMI’s shareholders approved the Philip Morris International Inc. 2017 Performance Incentive Plan (the “2017 Plan”). The 2017 Plan replaced the 2012 Performance Incentive Plan, and there will be no additional grants under the replaced plan. Under the 2017 Plan, PMI may grant to eligible employees restricted shares and restricted share units, performance-based cash incentive awards and performance-based equity awards. Up to 25 million shares of PMI’s common stock may be issued under the 2017 Plan. At March 31, 2019, shares available for grant under the 2017 Plan were 20,190,170. In May 2017, PMI’s shareholders also approved the Philip Morris International Inc. 2017 Stock Compensation Plan for Non-Employee Directors (the “2017 Non-Employee Directors Plan”). The 2017 Non-Employee Directors Plan replaced the 2008 Stock Compensation Plan for Non-Employee Directors, and there will be no additional grants under the replaced plan. A non-employee director is defined as a member of the PMI Board of Directors who is not a full-time employee of PMI or of any corporation in which PMI owns, directly or indirectly, stock possessing at least 50% of the total combined voting power of all classes of stock entitled to vote in the election of directors in such corporation. Up to 1 million shares of PMI common stock may be awarded under the 2017 Non-Employee Directors Plan. At March 31, 2019, shares available for grant under the plan were 974,344. Restricted share unit (RSU) awards During the three months ended March 31, 2019 and 2018, shares granted to eligible employees, the weighted-average grant date fair value per share and the recorded compensation expense related to RSU awards were as follows:
As of March 31, 2019, PMI had $203 million of total unrecognized compensation cost related to non-vested RSU awards. The cost is recognized over the original restriction period of the awards, which is typically three years after the date of the award, or upon death, disability or reaching the age of 58. During the three months ended March 31, 2019, 1,022,598 RSU awards vested. The grant date fair value of all the vested awards was approximately $91 million. The total fair value of RSU awards that vested during the three months ended March 31, 2019 was approximately $86 million. Performance share unit (PSU) awards During the three months ended March 31, 2019 and 2018, PMI granted PSU awards to certain executives. The PSU awards require the achievement of certain performance factors, which are predetermined at the time of grant, typically over a three-year performance cycle with performance metrics for such PSUs consisting of PMI’s Total Shareholder Return (TSR) relative to a predetermined peer group and on an absolute basis (50% weight), PMI’s currency-neutral compound annual adjusted operating income growth rate, excluding acquisitions (30% weight), and PMI’s performance against specific measures of PMI’s transformation (20% weight). The aggregate of the weighted performance factors for the three metrics determines the percentage of PSUs that will vest at the end of the three-year performance cycle. The minimum percentage of such PSUs that can vest is zero, with a target percentage of 100 and a maximum percentage of 200. Each such vested PSU entitles the participant to one share of common stock. An aggregate weighted PSU performance factor of 100 will result in the targeted number of PSUs being vested. At the end of the performance cycle, participants are entitled to an amount equivalent to the accumulated dividends paid on common stock during the performance cycle for the number of shares earned. During the three months ended March 31, 2019 and 2018, shares granted to eligible employees, the grant date fair value per share and the recorded compensation expense related to PSU awards were as follows:
The grant date fair value of the PSU awards subject to the other performance factors was determined by using the average of the high and low market price of PMI’s stock at the date of the grant. The grant date fair value of the PSU market based awards subject to the TSR performance factor was determined by using the Monte Carlo simulation model. The following assumptions were used to determine the grant date fair value of the PSU awards subject to the TSR performance factor:
(a) Based on the U.S. Treasury yield curve. (b) Determined using the observed historical volatility. (c) Determined using a weighted-average of historical and implied volatility. As of March 31, 2019, PMI had $52 million of total unrecognized compensation cost related to non-vested PSU awards. The cost is recognized over the performance cycle of the awards, or upon death, disability or reaching the age of 58. During the three months ended March 31, 2019, 330,616 PSU awards vested. The grant date fair value of all the vested awards was approximately $32 million. The total fair value of PSU awards that vested during the three months ended March 31, 2019 was approximately $28 million. |
Benefit Plans |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Retirement Benefits [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Benefit Plans | Benefit Plans: Pension coverage for employees of PMI’s subsidiaries is provided, to the extent deemed appropriate, through separate plans, many of which are governed by local statutory requirements. In addition, PMI provides health care and other benefits to substantially all U.S. retired employees and certain non-U.S. retired employees. In general, health care benefits for non-U.S. retired employees are covered through local government plans. Pension and other employee benefit costs per the condensed consolidated statements of earnings consisted of the following:
Pension Plans Components of Net Periodic Benefit Cost Net periodic pension cost consisted of the following:
(1) Primarily non-U.S. based defined benefit retirement plans. Employer Contributions PMI makes, and plans to make, contributions, to the extent that they are tax deductible and to meet specific funding requirements of its funded pension plans. Employer contributions of $17 million were made to the pension plans during the three months ended March 31, 2019. Currently, PMI anticipates making additional contributions during the remainder of 2019 of approximately $110 million to its pension plans, based on current tax and benefit laws. However, this estimate is subject to change as a result of changes in tax and other benefit laws, as well as asset performance significantly above or below the assumed long-term rate of return on pension assets, or changes in interest and currency rates. |
Goodwill and Other Intangible Assets, net |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and Other Intangible Assets, net | Goodwill and Other Intangible Assets, net: The movements in goodwill were as follows:
At March 31, 2019, goodwill primarily reflects PMI’s acquisitions in Colombia, Greece, Indonesia, Mexico, Pakistan and Serbia, as well as the business combination in the Philippines. For details on the deconsolidation of RBH, see Note 20. Deconsolidation of RBH. Details of other intangible assets were as follows:
* Includes farmer contracts and intellectual property rights Non-amortizable intangible assets substantially consist of trademarks from PMI’s acquisitions in Indonesia and Mexico. The increase since December 31, 2018 was due to currency movements of $20 million. The decrease in the gross carrying amount of amortizable intangible assets from December 31, 2018 was mainly due to the deconsolidation of RBH's trademarks of ($275 million) and distribution network of ($29 million), partially offset by currency movements of $4 million. The decrease in the accumulated amortization from December 31, 2018 was mainly due to the deconsolidation of RBH's trademarks of ($133 million) and distribution network of ($18 million), partially offset by the 2019 amortization of $19 million. Amortization expense for each of the next five years is estimated to be $65 million or less, assuming no additional transactions occur that require the amortization of intangible assets. |
Financial Instruments |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative Instruments and Hedging Activities Disclosure [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Instruments | Financial Instruments: Overview PMI operates in markets outside of the United States of America, with manufacturing and sales facilities in various locations around the world. PMI utilizes certain financial instruments to manage foreign currency and interest rate exposure. Derivative financial instruments are used by PMI principally to reduce exposures to market risks resulting from fluctuations in foreign currency exchange and interest rates by creating offsetting exposures. PMI is not a party to leveraged derivatives and, by policy, does not use derivative financial instruments for speculative purposes. Financial instruments qualifying for hedge accounting must maintain a specified level of effectiveness between the hedging instrument and the item being hedged, both at inception and throughout the hedged period. PMI formally documents the nature and relationships between the hedging instruments and hedged items, as well as its risk-management objectives, strategies for undertaking the various hedge transactions and method of assessing hedge effectiveness. Additionally, for hedges of forecasted transactions, the significant characteristics and expected terms of the forecasted transaction must be specifically identified, and it must be probable that each forecasted transaction will occur. If it were deemed probable that the forecasted transaction would not occur, the gain or loss would be recognized in earnings. PMI uses deliverable and non-deliverable forward foreign exchange contracts, foreign currency swaps and foreign currency options, collectively referred to as foreign exchange contracts ("foreign exchange contracts"), and interest rate contracts to mitigate its exposure to changes in exchange and interest rates from third-party and intercompany actual and forecasted transactions. Both foreign exchange contracts and interest rate contracts are collectively referred to as derivative contracts ("derivative contracts"). The primary currencies to which PMI is exposed include the Australian dollar, Euro, Indonesian rupiah, Japanese yen, Mexican peso, Philippine peso, Russian ruble, Swiss franc and Turkish lira. At March 31, 2019, PMI had contracts with aggregate notional amounts of $25.4 billion of which $4.8 billion related to cash flow hedges, $8.9 billion related to hedges of net investments in foreign operations and $11.7 billion related to other derivatives that primarily offset currency exposures on intercompany financing. The fair value of PMI’s derivative contracts included in the condensed consolidated balance sheets as of March 31, 2019 and December 31, 2018, were as follows:
For the three months ended March 31, 2019 and 2018, PMI's cash flow and net investment hedging instruments impacted the condensed consolidated statements of earnings and comprehensive earnings as follows:
Cash Flow Hedges PMI has entered into derivative contracts to hedge the foreign currency exchange and interest rate risks related to certain forecasted transactions. Gains and losses associated with qualifying cash flow hedge contracts is deferred as a component of accumulated other comprehensive losses until the underlying hedged transactions are reported in PMI’s condensed consolidated statements of earnings. As of March 31, 2019, PMI has hedged forecasted transactions for periods not exceeding the next twenty-one months with the exception of one derivative contract that expires in May 2024. The impact of these hedges is primarily included in operating cash flows on PMI’s condensed consolidated statements of cash flows. Hedges of Net Investments in Foreign Operations PMI designates certain foreign currency denominated debt and derivative contracts as net investment hedges, primarily of its Euro net assets. For the three months ended March 31, 2019 and 2018, these hedges of net investments resulted in gains (losses), net of income taxes, of $291 million and $(757) million, respectively, principally related to changes in the exchange rates between the Euro and U.S. dollar. These gains (losses) were reported as a component of accumulated other comprehensive losses within currency translation adjustments, and were substantially offset by the losses and gains generated on the underlying assets. For the three months ended March 31, 2019 and 2018, the gains for amounts excluded from the effectiveness testing recognized in earnings were $56 million and $67 million, respectively, and were accounted for in interest expense, net, on the condensed consolidated statement of earnings. The premiums paid for, and settlements of, net investment hedges are included in investing cash flows on PMI’s condensed consolidated statements of cash flows. Other Derivatives PMI has entered into derivative contracts to hedge the foreign currency exchange and interest rate risks related to intercompany loans between certain subsidiaries, and third-party loans. While effective as economic hedges, no hedge accounting is applied for these contracts; therefore, the unrealized gains (losses) relating to these contracts are reported in marketing, administration and research costs in PMI’s condensed consolidated statements of earnings. For the three months ended March 31, 2019 and 2018, the gains (losses) from contracts for which PMI did not apply hedge accounting were $(7) million and $95 million, respectively. The gains (losses) from these contracts substantially offset the losses and gains generated by the underlying intercompany and third-party loans being hedged. For the three months ended March 31, 2019 and 2018, the net impact of these contracts on the condensed consolidated statements of earnings was not material. Qualifying Hedging Activities Reported in Accumulated Other Comprehensive Losses Derivative gains or losses reported in accumulated other comprehensive losses are a result of qualifying hedging activity. Transfers of these gains or losses to earnings are offset by the corresponding gains or losses on the underlying hedged item. Hedging activity affected accumulated other comprehensive losses, net of income taxes, as follows:
At March 31, 2019, PMI expects $23 million of derivative gains that are included in accumulated other comprehensive losses to be reclassified to the condensed consolidated statement of earnings within the next 12 months. These gains are expected to be substantially offset by the statement of earnings impact of the respective hedged transactions. Contingent Features PMI’s derivative instruments do not contain contingent features. Credit Exposure and Credit Risk PMI is exposed to credit loss in the event of non-performance by counterparties. While PMI does not anticipate non-performance, its risk is limited to the fair value of the financial instruments less any cash collateral received or pledged. PMI actively monitors its exposure to credit risk through the use of credit approvals and credit limit and by selecting and continuously monitoring a diverse group of major international banks and financial institutions as counterparties. Fair Value See Note 11. Fair Value Measurements and Note 13. Balance Sheet Offsetting for additional discussion of derivative financial instruments. |
Earnings Per Share |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share | Earnings Per Share: Basic and diluted earnings per share (“EPS”) were calculated using the following:
Unvested share-based payment awards that contain non-forfeitable rights to dividends or dividend equivalents are participating securities and therefore are included in PMI’s earnings per share calculation pursuant to the two-class method. For the 2019 and 2018 computations, there were no antidilutive stock awards. |
Segment Reporting |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting | Segment Reporting: PMI’s subsidiaries and affiliates are engaged in the manufacture and sale of cigarettes and other nicotine-containing products, including RRPs, in markets outside of the United States of America. Reportable segments for PMI are organized by geographic region and managed by segment managers who are responsible for the operating and financial results of the regions inclusive of all product categories sold in the region. PMI’s reportable segments are the European Union; Eastern Europe; Middle East & Africa; South & Southeast Asia; East Asia & Australia; and Latin America & Canada. PMI records net revenues and operating income to its segments based upon the geographic area in which the customer resides. PMI’s chief operating decision maker evaluates segment performance and allocates resources based on regional operating income, which includes results from all product categories sold in each region. PMI disaggregates its net revenue from contracts with customers by both geographic location and product category for each of PMI's six reportable segments, as PMI believes this best depicts how the nature, amount, timing and uncertainty of its revenue and cash flows are affected by economic factors. Segment data were as follows:
Items affecting the comparability of results from operations were as follows:
PMI's net revenues by product category were as follows:
Note: Sum of product categories or Regions might not foot to total PMI due to roundings. Net revenues related to combustible products refer to the operating revenues generated from the sale of these products, including shipping and handling charges billed to customers, net of sales and promotion incentives, and excise taxes. These net revenue amounts consist of the sale of PMI's cigarettes and other tobacco products combined. Other tobacco products primarily include roll-your-own and make-your-own cigarettes, pipe tobacco, cigars and cigarillos and do not include reduced-risk products. Net revenues related to reduced-risk products refer to the operating revenues generated from the sale of these products, including shipping and handling charges billed to customers, net of sales and promotion incentives, and excise taxes. These net revenue amounts consist of the sale of PMI's heated tobacco units, IQOS devices and related accessories, and other nicotine-containing products, which primarily include our e-vapor products. PMI recognizes revenue, when control is transferred to the customer, typically either upon shipment or delivery of goods. |
Contingencies |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitments and Contingencies Disclosure [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Contingencies | Contingencies: Tobacco-Related Litigation Legal proceedings covering a wide range of matters are pending or threatened against us, and/or our subsidiaries, and/or our indemnitees in various jurisdictions. Our indemnitees include distributors, licensees, and others that have been named as parties in certain cases and that we have agreed to defend, as well as to pay costs and some or all of judgments, if any, that may be entered against them. Pursuant to the terms of the Distribution Agreement between Altria Group, Inc. (“Altria”) and PMI, PMI will indemnify Altria and Philip Morris USA Inc. (“PM USA”), a U.S. tobacco subsidiary of Altria, for tobacco product claims based in substantial part on products manufactured by PMI or contract manufactured for PMI by PM USA, and PM USA will indemnify PMI for tobacco product claims based in substantial part on products manufactured by PM USA, excluding tobacco products contract manufactured for PMI. It is possible that there could be adverse developments in pending cases against us and our subsidiaries. An unfavorable outcome or settlement of pending tobacco-related litigation could encourage the commencement of additional litigation. Damages claimed in some of the tobacco-related litigation are significant and, in certain cases in Brazil, Canada, Israel and Nigeria, range into the billions of U.S. dollars. The variability in pleadings in multiple jurisdictions, together with the actual experience of management in litigating claims, demonstrate that the monetary relief that may be specified in a lawsuit bears little relevance to the ultimate outcome. Much of the tobacco-related litigation is in its early stages, and litigation is subject to uncertainty. However, as discussed below, we have to date been largely successful in defending tobacco-related litigation. We and our subsidiaries record provisions in the consolidated financial statements for pending litigation when we determine that an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. At the present time, except as stated otherwise in this Note 8. Contingencies, while it is reasonably possible that an unfavorable outcome in a case may occur, after assessing the information available to it (i) management has not concluded that it is probable that a loss has been incurred in any of the pending tobacco-related cases; (ii) management is unable to estimate the possible loss or range of loss for any of the pending tobacco-related cases; and (iii) accordingly, no estimated loss has been accrued in the consolidated financial statements for unfavorable outcomes in these cases, if any. Legal defense costs are expensed as incurred. It is possible that our consolidated results of operations, cash flows or financial position could be materially affected in a particular fiscal quarter or fiscal year by an unfavorable outcome or settlement of certain pending litigation. Nevertheless, although litigation is subject to uncertainty, we and each of our subsidiaries named as a defendant believe, and each has been so advised by counsel handling the respective cases, that we have valid defenses to the litigation pending against us, as well as valid bases for appeal of adverse verdicts. All such cases are, and will continue to be, vigorously defended. However, we and our subsidiaries may enter into settlement discussions in particular cases if we believe it is in our best interests to do so. CCAA Proceedings and Stay of Tobacco-Related Cases Pending in Canada As a result of the Court of Appeal of Quebec’s decision in both the Létourneau and Blais cases described below, our subsidiary, Rothmans, Benson & Hedges Inc. (“RBH”), and the other defendants, JTI Macdonald Corp., and Imperial Tobacco Canada Limited, sought protection in the Ontario Superior Court of Justice under the Companies’ Creditors Arrangement Act (“CCAA”) on March 22, March 8, and March 12, respectively. CCAA is a Canadian federal law that permits a Canadian business to restructure its affairs while carrying on its business in the ordinary course. The initial CCAA order made by the Ontario Superior Court on March 22, 2019 authorizes RBH to pay all expenses incurred in carrying on its business in the ordinary course after the CCAA filing, including obligations to employees, vendors, and suppliers. As further described in Note 20. Deconsolidation of RBH, RBH is now deconsolidated from our consolidated financial statements. As part of the CCAA proceedings, there is currently a comprehensive stay up to and including June 28, 2019 of all tobacco-related litigation pending in Canada against RBH and the other defendants, including PMI and our indemnitees (PM USA and Altria), namely, the smoking and health class actions filed in various Canadian provinces and health care cost recovery actions. These proceedings are presented below under the caption “Stayed Litigation — Canada.” Ernst & Young Inc. has been appointed as monitor of RBH in the CCAA proceedings. In accordance with the CCAA process, as the parties work towards a plan of arrangement or compromise, it is anticipated that the court will set additional hearings and further extend the stay of proceedings. On April 17, 2019, the Ontario Superior Court ruled that RBH and the other defendants will not be allowed to file an application to the Supreme Court of Canada for leave to appeal the Court of Appeal’s decision in the Létourneau and the Blais cases so long as the comprehensive stay of all tobacco-related litigation in Canada remains in effect and that the time period to file the application would be extended by the stay period. While RBH believes that the findings of liability and damages in both Létourneau and the Blais cases were incorrect, the CCAA proceedings will provide a forum for RBH to seek resolution through a plan of arrangement or compromise of all tobacco-related litigation pending in Canada. It is not possible to predict the resolution of the underlying legal proceedings or the length of the CCAA process. Stayed Litigation — Canada Smoking and Health Litigation — Canada In the first class action pending in Canada, Conseil Québécois Sur Le Tabac Et La Santé and Jean-Yves Blais v. Imperial Tobacco Ltd., Rothmans, Benson & Hedges Inc. and JTI-Macdonald Corp., Quebec Superior Court, Canada, filed in November 1998, RBH and other Canadian manufacturers (Imperial Tobacco Canada Ltd. and JTI-Macdonald Corp.) are defendants. The plaintiffs, an anti-smoking organization and an individual smoker, sought compensatory and punitive damages for each member of the class who allegedly suffers from certain smoking-related diseases. The class was certified in 2005. The trial court issued its judgment on May 27, 2015. The trial court found RBH and two other Canadian manufacturers liable and found that the class members’ compensatory damages totaled approximately CAD 15.5 billion, including pre-judgment interest (approximately $11.6 billion). The trial court awarded compensatory damages on a joint and several liability basis, allocating 20% to our subsidiary (approximately CAD 3.1 billion, including pre-judgment interest (approximately $2.32 billion)). In addition, the trial court awarded CAD 90,000 (approximately $67,370) in punitive damages, allocating CAD 30,000 (approximately $22,460) to RBH. The trial court estimated the disease class at 99,957 members. RBH appealed to the Court of Appeal of Quebec. In October 2015, the Court of Appeal ordered RBH to furnish security totaling CAD 226 million (approximately $169.2 million) to cover both the Létourneau and Blais cases, which RBH has paid in installments through March 2017. The Court of Appeal ordered Imperial Tobacco Canada Ltd. to furnish security totaling CAD 758 million (approximately $567.4 million) in installments through June 2017. JTI Macdonald Corp. was not required to furnish security in accordance with plaintiffs’ motion. The Court of Appeal ordered that the security is payable upon a final judgment of the Court of Appeal affirming the trial court’s judgment or upon further order of the Court of Appeal. On March 1, 2019, the Court of Appeal issued a decision largely affirming the trial court’s findings of liability and the compensatory and punitive damages award while reducing the total amount of compensatory damages to approximately CAD 13.5 billion including interest (approximately $10.1 billion) due to the trial court’s error in the calculation of interest. The compensatory damages award is on a joint and several basis with an allocation of 20% to RBH (approximately CAD 2.7 billion, including pre-judgment interest (approximately $2.02 billion)). The Court of Appeal upheld the trial court’s findings that defendants violated the Civil Code of Quebec, the Quebec Charter of Human Rights and Freedoms, and the Quebec Consumer Protection Act by failing to warn adequately of the dangers of smoking and by conspiring to prevent consumers from learning of the dangers of smoking. The Court of Appeal further held that the plaintiffs either need not prove, or had adequately proven, that these faults were a cause of the class members’ injuries. In accordance with the judgment, defendants are required to deposit their respective portions of the damages awarded in both the Létourneau case described below and the Blais case, approximately CAD 1.1 billion (approximately $823.4 million), into trust accounts within 60 days. RBH’s share of the deposit is approximately CAD 257 million (approximately $192.4 million). PMI recorded a pre-tax charge of $194 million in its consolidated results, representing $142 million net of tax, as tobacco litigation-related expense, in the first quarter of 2019. The charge reflects PMI’s assessment of the portion of the judgment that it believes is probable and estimable at this time and corresponds to the trust account deposit required by the judgment. In the second class action pending in Canada, Cecilia Létourneau v. Imperial Tobacco Ltd., Rothmans, Benson & Hedges Inc. and JTI-Macdonald Corp., Quebec Superior Court, Canada, filed in September 1998, RBH and other Canadian manufacturers (Imperial Tobacco Canada Ltd. and JTI-Macdonald Corp.) are defendants. The plaintiff, an individual smoker, sought compensatory and punitive damages for each member of the class who is deemed addicted to smoking. The class was certified in 2005. The trial court issued its judgment on May 27, 2015. The trial court found RBH and two other Canadian manufacturers liable and awarded a total of CAD 131 million (approximately $98.1 million) in punitive damages, allocating CAD 46 million (approximately $34.4 million) to RBH. The trial court estimated the size of the addiction class at 918,000 members but declined to award compensatory damages to the addiction class because the evidence did not establish the claims with sufficient accuracy. The trial court found that a claims process to allocate the awarded punitive damages to individual class members would be too expensive and difficult to administer. On March 1, 2019, the Court of Appeal issued a decision largely affirming the trial court’s findings of liability and the total amount of punitive damages awarded allocating CAD 57 million including interest (approximately $42.7 million) to RBH. See the Blais description above and Note 20. Deconsolidation of RBH below for further detail concerning the security order pertaining to both Létourneau and Blais cases and the impact of the decision on PMI’s financial statements. RBH and PMI believe the findings of liability and damages in both Létourneau and the Blais cases were incorrect and in contravention of applicable law on several grounds including the following: (i) defendants had no obligation to warn class members who knew, or should have known, of the risks of smoking; (ii) defendants cannot be liable to class members who would have smoked regardless of what warnings were given; and (iii) defendants cannot be liable to all class members given the individual differences between class members. In the third class action pending in Canada, Kunta v. Canadian Tobacco Manufacturers' Council, et al., The Queen's Bench, Winnipeg, Canada, filed June 12, 2009, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker, alleges her own addiction to tobacco products and chronic obstructive pulmonary disease (“COPD”), severe asthma, and mild reversible lung disease resulting from the use of tobacco products. She is seeking compensatory and punitive damages on behalf of a proposed class comprised of all smokers, their estates, dependents and family members, as well as restitution of profits, and reimbursement of government health care costs allegedly caused by tobacco products. In the fourth class action pending in Canada, Adams v. Canadian Tobacco Manufacturers' Council, et al., The Queen's Bench, Saskatchewan, Canada, filed July 10, 2009, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker, alleges her own addiction to tobacco products and COPD resulting from the use of tobacco products. She is seeking compensatory and punitive damages on behalf of a proposed class comprised of all smokers who have smoked a minimum of 25,000 cigarettes and have allegedly suffered, or suffer, from COPD, emphysema, heart disease, or cancer, as well as restitution of profits. In the fifth class action pending in Canada, Semple v. Canadian Tobacco Manufacturers' Council, et al., The Supreme Court (trial court), Nova Scotia, Canada, filed June 18, 2009, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker, alleges his own addiction to tobacco products and COPD resulting from the use of tobacco products. He is seeking compensatory and punitive damages on behalf of a proposed class comprised of all smokers, their estates, dependents and family members, as well as restitution of profits, and reimbursement of government health care costs allegedly caused by tobacco products. In the sixth class action pending in Canada, Dorion v. Canadian Tobacco Manufacturers' Council, et al., The Queen's Bench, Alberta, Canada, filed June 15, 2009, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker, alleges her own addiction to tobacco products and chronic bronchitis and severe sinus infections resulting from the use of tobacco products. She is seeking compensatory and punitive damages on behalf of a proposed class comprised of all smokers, their estates, dependents and family members, restitution of profits, and reimbursement of government health care costs allegedly caused by tobacco products. To date, we, our subsidiaries, and our indemnitees have not been properly served with the complaint. In the seventh class action pending in Canada, McDermid v. Imperial Tobacco Canada Limited, et al., Supreme Court, British Columbia, Canada, filed June 25, 2010, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker, alleges his own addiction to tobacco products and heart disease resulting from the use of tobacco products. He is seeking compensatory and punitive damages on behalf of a proposed class comprised of all smokers who were alive on June 12, 2007, and who suffered from heart disease allegedly caused by smoking, their estates, dependents and family members, plus disgorgement of revenues earned by the defendants from January 1, 1954, to the date the claim was filed. In the eighth class action pending in Canada, Bourassa v. Imperial Tobacco Canada Limited, et al., Supreme Court, British Columbia, Canada, filed June 25, 2010, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, the heir to a deceased smoker, alleges that the decedent was addicted to tobacco products and suffered from emphysema resulting from the use of tobacco products. She is seeking compensatory and punitive damages on behalf of a proposed class comprised of all smokers who were alive on June 12, 2007, and who suffered from chronic respiratory diseases allegedly caused by smoking, their estates, dependents and family members, plus disgorgement of revenues earned by the defendants from January 1, 1954, to the date the claim was filed. In December 2014, plaintiff filed an amended statement of claim. In the ninth class action pending in Canada, Suzanne Jacklin v. Canadian Tobacco Manufacturers' Council, et al., Ontario Superior Court of Justice, filed June 20, 2012, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker, alleges her own addiction to tobacco products and COPD resulting from the use of tobacco products. She is seeking compensatory and punitive damages on behalf of a proposed class comprised of all smokers who have smoked a minimum of 25,000 cigarettes and have allegedly suffered, or suffer, from COPD, heart disease, or cancer, as well as restitution of profits. Health Care Cost Recovery Litigation — Canada In the first health care cost recovery case pending in Canada, Her Majesty the Queen in Right of British Columbia v. Imperial Tobacco Limited, et al., Supreme Court, British Columbia, Vancouver Registry, Canada, filed January 24, 2001, we, RBH, our indemnitee (PM USA), and other members of the industry are defendants. The plaintiff, the government of the province of British Columbia, brought a claim based upon legislation enacted by the province authorizing the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, resulting from a “tobacco related wrong.” In the second health care cost recovery case filed in Canada, Her Majesty the Queen in Right of New Brunswick v. Rothmans Inc., et al., Court of Queen's Bench of New Brunswick, Trial Court, New Brunswick, Fredericton, Canada, filed March 13, 2008, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of New Brunswick based on legislation enacted in the province. This legislation is similar to the law introduced in British Columbia that authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.” In the third health care cost recovery case filed in Canada, Her Majesty the Queen in Right of Ontario v. Rothmans Inc., et al., Ontario Superior Court of Justice, Toronto, Canada, filed September 29, 2009, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of Ontario based on legislation enacted in the province. This legislation is similar to the laws introduced in British Columbia and New Brunswick that authorize the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.” In the fourth health care cost recovery case filed in Canada, Attorney General of Newfoundland and Labrador v. Rothmans Inc., et al., Supreme Court of Newfoundland and Labrador, St. Johns, Canada, filed February 8, 2011, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of Newfoundland and Labrador based on legislation enacted in the province that is similar to the laws introduced in British Columbia, New Brunswick and Ontario. The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.” In the fifth health care cost recovery case filed in Canada, Attorney General of Quebec v. Imperial Tobacco Limited, et al., Superior Court of Quebec, Canada, filed June 8, 2012, we, RBH, our indemnitee (PM USA), and other members of the industry are defendants. The claim was filed by the government of the province of Quebec based on legislation enacted in the province that is similar to the laws enacted in several other Canadian provinces. The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.” In the sixth health care cost recovery case filed in Canada, Her Majesty in Right of Alberta v. Altria Group, Inc., et al., Supreme Court of Queen's Bench Alberta, Canada, filed June 8, 2012, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of Alberta based on legislation enacted in the province that is similar to the laws enacted in several other Canadian provinces. The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.” In the seventh health care cost recovery case filed in Canada, Her Majesty the Queen in Right of the Province of Manitoba v. Rothmans, Benson & Hedges, Inc., et al., The Queen's Bench, Winnipeg Judicial Centre, Canada, filed May 31, 2012, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of Manitoba based on legislation enacted in the province that is similar to the laws enacted in several other Canadian provinces. The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.” In the eighth health care cost recovery case filed in Canada, The Government of Saskatchewan v. Rothmans, Benson & Hedges Inc., et al., Queen's Bench, Judicial Centre of Saskatchewan, Canada, filed June 8, 2012, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of Saskatchewan based on legislation enacted in the province that is similar to the laws enacted in several other Canadian provinces. The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.” In the ninth health care cost recovery case filed in Canada, Her Majesty the Queen in Right of the Province of Prince Edward Island v. Rothmans, Benson & Hedges Inc., et al., Supreme Court of Prince Edward Island (General Section), Canada, filed September 10, 2012, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of Prince Edward Island based on legislation enacted in the province that is similar to the laws enacted in several other Canadian provinces. The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.” In the tenth health care cost recovery case filed in Canada, Her Majesty the Queen in Right of the Province of Nova Scotia v. Rothmans, Benson & Hedges Inc., et al., Supreme Court of Nova Scotia, Canada, filed January 2, 2015, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of Nova Scotia based on legislation enacted in the province that is similar to the laws enacted in several other Canadian provinces. The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.” __________ The table below lists the number of tobacco-related cases pertaining to combustible products pending against us and/or our subsidiaries or indemnitees as of April 23, 2019, April 24, 2018 and April 25, 2017:¹
Since 1995, when the first tobacco-related litigation was filed against a PMI entity, 493 Smoking and Health, Label-Related, Health Care Cost Recovery, and Public Civil Actions in which we and/or one of our subsidiaries and/or indemnitees were a defendant have been terminated in our favor. Thirteen cases have had decisions in favor of plaintiffs. Nine of these cases have subsequently reached final resolution in our favor and four remain on appeal. The table below lists the verdict and significant post-trial developments in the four pending cases where a verdict was returned in favor of the plaintiff:
______ ¹ Includes cases pending in Canada.
Pending claims related to tobacco products generally fall within the following categories: Smoking and Health Litigation: These cases primarily allege personal injury and are brought by individual plaintiffs or on behalf of a class or purported class of individual plaintiffs. Plaintiffs' allegations of liability in these cases are based on various theories of recovery, including negligence, gross negligence, strict liability, fraud, misrepresentation, design defect, failure to warn, breach of express and implied warranties, violations of deceptive trade practice laws and consumer protection statutes. Plaintiffs in these cases seek various forms of relief, including compensatory and other damages, and injunctive and equitable relief. Defenses raised in these cases include licit activity, failure to state a claim, lack of defect, lack of proximate cause, assumption of the risk, contributory negligence, and statute of limitations. As of April 23, 2019, there were a number of smoking and health cases pending against us, our subsidiaries or indemnitees, as follows:
The class actions pending in Canada are described above under the caption “Smoking and Health Litigation — Canada.” In the class action pending in Brazil, The Smoker Health Defense Association (ADESF) v. Souza Cruz, S.A. and Philip Morris Marketing, S.A., Nineteenth Lower Civil Court of the Central Courts of the Judiciary District of São Paulo, Brazil, filed July 25, 1995, our subsidiary and another member of the industry are defendants. The plaintiff, a consumer organization, is seeking damages for all addicted smokers and former smokers, and injunctive relief. In 2004, the trial court found defendants liable without hearing evidence and awarded “moral damages” of R$1,000 (approximately $255) per smoker per full year of smoking plus interest at the rate of 1% per month, as of the date of the ruling. The court did not award actual damages, which were to be assessed in the second phase of the case. The size of the class was not estimated. Defendants appealed to the São Paulo Court of Appeals, which annulled the ruling in November 2008, finding that the trial court had inappropriately ruled without hearing evidence and returned the case to the trial court for further proceedings. In May 2011, the trial court dismissed the claim. In February 2015, the appellate court unanimously dismissed plaintiff's appeal. In September 2015, plaintiff appealed to the Superior Court of Justice. In February 2017, the Chief Justice of the Superior Court of Justice denied plaintiff's appeal. In March 2017, plaintiff filed an en banc appeal to the Superior Court of Justice. In addition, the defendants filed a constitutional appeal to the Federal Supreme Tribunal on the basis that plaintiff did not have standing to bring the lawsuit. Both appeals are still pending. Health Care Cost Recovery Litigation: These cases, brought by governmental and non-governmental plaintiffs, seek reimbursement of health care cost expenditures allegedly caused by tobacco products. Plaintiffs' allegations of liability in these cases are based on various theories of recovery including unjust enrichment, negligence, negligent design, strict liability, breach of express and implied warranties, violation of a voluntary undertaking or special duty, fraud, negligent misrepresentation, conspiracy, public nuisance, defective product, failure to warn, sale of cigarettes to minors, and claims under statutes governing competition and deceptive trade practices. Plaintiffs in these cases seek various forms of relief including compensatory and other damages, and injunctive and equitable relief. Defenses raised in these cases include lack of proximate cause, remoteness of injury, failure to state a claim, adequate remedy at law, “unclean hands” (namely, that plaintiffs cannot obtain equitable relief because they participated in, and benefited from, the sale of cigarettes), and statute of limitations. As of April 23, 2019, there were 16 health care cost recovery cases pending against us, our subsidiaries or indemnitees in Canada (10), Korea (1) and Nigeria (5), compared with 16 such cases on April 24, 2018 and 16 such cases on April 25, 2017. The health care cost recovery actions pending in Canada are described above under the caption “Health Care Cost Recovery Litigation — Canada.” In the first health care cost recovery case in Nigeria, The Attorney General of Lagos State v. British American Tobacco (Nigeria) Limited, et al., High Court of Lagos State, Lagos, Nigeria, filed March 13, 2008, we and other members of the industry are defendants. Plaintiff seeks reimbursement for the cost of treating alleged smoking-related diseases for the past 20 years, payment of anticipated costs of treating alleged smoking-related diseases for the next 20 years, various forms of injunctive relief, plus punitive damages. We are in the process of making challenges to service and the court's jurisdiction. Currently, the case is stayed in the trial court pending the appeals of certain co-defendants relating to service objections. In the second health care cost recovery case in Nigeria, The Attorney General of Kano State v. British American Tobacco (Nigeria) Limited, et al., High Court of Kano State, Kano, Nigeria, filed May 9, 2007, we and other members of the industry are defendants. Plaintiff seeks reimbursement for the cost of treating alleged smoking-related diseases for the past 20 years, payment of anticipated costs of treating alleged smoking-related diseases for the next 20 years, various forms of injunctive relief, plus punitive damages. We are in the process of making challenges to service and the court's jurisdiction. Currently, the case is stayed in the trial court pending the appeals of certain co-defendants relating to service objections. In the third health care cost recovery case in Nigeria, The Attorney General of Gombe State v. British American Tobacco (Nigeria) Limited, et al., High Court of Gombe State, Gombe, Nigeria, filed October 17, 2008, we and other members of the industry are defendants. Plaintiff seeks reimbursement for the cost of treating alleged smoking-related diseases for the past 20 years, payment of anticipated costs of treating alleged smoking-related diseases for the next 20 years, various forms of injunctive relief, plus punitive damages. In February 2011, the court ruled that the plaintiff had not complied with the procedural steps necessary to serve us. As a result of this ruling, plaintiff must re-serve its claim. We have not yet been re-served. In the fourth health care cost recovery case in Nigeria, The Attorney General of Oyo State, et al., v. British American Tobacco (Nigeria) Limited, et al., High Court of Oyo State, Ibadan, Nigeria, filed May 25, 2007, we and other members of the industry are defendants. Plaintiffs seek reimbursement for the cost of treating alleged smoking-related diseases for the past 20 years, payment of anticipated costs of treating alleged smoking-related diseases for the next 20 years, various forms of injunctive relief, plus punitive damages. We challenged service as improper. In June 2010, the court ruled that plaintiffs did not have leave to serve the writ of summons on the defendants and that they must re-serve the writ. We have not yet been re-served. In the fifth health care cost recovery case in Nigeria, The Attorney General of Ogun State v. British American Tobacco (Nigeria) Limited, et al., High Court of Ogun State, Abeokuta, Nigeria, filed February 26, 2008, we and other members of the industry are defendants. Plaintiff seeks reimbursement for the cost of treating alleged smoking-related diseases for the past 20 years, payment of anticipated costs of treating alleged smoking-related diseases for the next 20 years, various forms of injunctive relief, plus punitive damages. In May 2010, the trial court rejected our service objections. We have appealed. In the health care cost recovery case in Korea, the National Health Insurance Service v. KT&G, et. al., filed April 14, 2014, our subsidiary and other Korean manufacturers are defendants. Plaintiff alleges that defendants concealed the health hazards of smoking, marketed to youth, added ingredients to make their products more harmful and addictive, and misled consumers into believing that Lights cigarettes are safer than regular cigarettes. The National Health Insurance Service seeks to recover damages allegedly incurred in treating 3,484 patients with small cell lung cancer, squamous cell lung cancer, and squamous cell laryngeal cancer from 2003 to 2012. The case is now in the evidentiary phase. Label-Related Cases: These cases, brought by individual plaintiffs, or on behalf of a class or purported class of individual plaintiffs, allege that the use of the descriptor “Lights” or other alleged misrepresentations or omissions of labeling information constitute fraudulent and misleading conduct. Plaintiffs' allegations of liability in these cases are based on various theories of recovery including misrepresentation, deception, and breach of consumer protection laws. Plaintiffs seek various forms of relief including restitution, injunctive relief, and compensatory and other damages. Defenses raised include lack of causation, lack of reliance, assumption of the risk, and statute of limitations. As of April 23, 2019, there were 7 label-related cases brought by individual plaintiffs in Italy (1) and Chile (6) pending against our subsidiaries, compared with 1 such case on April 24, 2018, and 1 such case on April 25, 2017, and one purported class action in Israel (1). An individual plaintiff filed a purported class action certification motion, Aharon Ringer v. Philip Morris Ltd. and Globrands Ltd., on July 18, 2017, in the Central District Court of Israel. Our Israeli affiliate and an Israeli importer and distributor for other multinational tobacco companies are defendants. Plaintiff seeks to represent a class of smokers in Israel who have purchased cigarettes imported by defendants since July 18, 2010. Plaintiff estimates the class size to be 7,000,000 smokers. Plaintiff alleges that defendants misled consumers by not disclosing sufficient information about carbon monoxide, tar, and nicotine yields of, and tobacco contained in, the imported cigarettes. Plaintiff seeks various forms of relief, including an order for defendants to label cigarette packs in accordance with plaintiff’s demands, and damages for misleading consumers, breach of autonomy and unjust enrichment. Pre-class certification hearings began in March 2019, and the next hearing has been scheduled for September 2019. Public Civil Actions: Claims have been filed either by an individual, or a public or private entity, seeking to protect collective or individual rights, such as the right to health, the right to information or the right to safety. Plaintiffs' allegations of liability in these cases are based on various theories of recovery including product defect, concealment, and misrepresentation. Plaintiffs in these cases seek various forms of relief including injunctive relief such as banning cigarettes, descriptors, smoking in certain places and advertising, as well as implementing communication campaigns and reimbursement of medical expenses incurred by public or private institutions. As of April 23, 2019, there were 2 public civil actions pending against our subsidiaries in Argentina (1) and Venezuela (1), compared with 2 such cases on April 24, 2018, and 2 such cases on April 25, 2017. In the public civil action in Argentina, Asociación Argentina de Derecho de Danos v. Massalin Particulares S.A., et al., Civil Court of Buenos Aires, Argentina, filed February 26, 2007, our subsidiary and another member of the industry are defendants. The plaintiff, a consumer association, seeks the establishment of a relief fund for reimbursement of medical costs associated with diseases allegedly caused by smoking. Our subsidiary filed its answer in September 2007. In March 2010, the case file was transferred to the Federal Court on Administrative Matters after the Civil Court granted plaintiff's request to add the national government as a co-plaintiff in the case. The case is currently in closing arguments. In the public civil action in Venezuela, Federation of Consumers and Users Associations (“FEVACU”), et al. v. National Assembly of Venezuela and the Venezuelan Ministry of Health, Constitutional Chamber of the Venezuelan Supreme Court, filed April 29, 2008, we were not named as a defendant, but the plaintiffs published a notice pursuant to court order, notifying all interested parties to appear in the case. In January 2009, our subsidiary appeared in the case in response to this notice. The plaintiffs purport to represent the right to health of the citizens of Venezuela and claim that the government failed to protect adequately its citizens' right to health. The claim asks the court to order the government to enact stricter regulations on the manufacture and sale of tobacco products. In addition, the plaintiffs ask the court to order companies involved in the tobacco industry to allocate a percentage of their “sales or benefits” to establish a fund to pay for the health care costs of treating smoking-related diseases. In October 2008, the court ruled that plaintiffs have standing to file the claim and that the claim meets the threshold admissibility requirements. In December 2012, the court admitted our subsidiary and BAT's subsidiary as interested third parties. In February 2013, our subsidiary answered the complaint. Reduced-Risk Products In Israel, an individual filed a purported class action certification motion, Adir Natan vs. Philip Morris Ltd., in June 2017 against our subsidiary with the Israeli District Court of Haifa related to the marketing of our Platform 1 product. Plaintiff alleges that our affiliate misleads consumers by marketing such a product as a "better alternative to smoking" and as a reduced-risk product, while not disclosing the risks associated with the product. Plaintiff alleges that this product is more addictive and more dangerous than cigarettes. Plaintiff claims that the first time he used this product, he experienced tightness in the chest, difficulty breathing, chills, nausea and dizziness. Plaintiff seeks damages on his behalf, and on behalf of the class (defined as all Platform 1 consumers in Israel), for personal injuries, emotional distress, breach of autonomy, and unjust enrichment. Pre-class certification hearings have been scheduled to begin in May 2019. Other Litigation The Department of Special Investigations of the government of Thailand ("DSI") conducted an investigation into alleged underpayment by our subsidiary, Philip Morris (Thailand) Limited ("PM Thailand"), of customs duties and excise taxes relating to imports from the Philippines covering the period 2003-2007. On January 18, 2016, the Public Prosecutor filed charges against our subsidiary and seven former and current employees in the Bangkok Criminal Court alleging that PM Thailand and the individual defendants jointly and with the intention to defraud the Thai government, under-declared import prices of cigarettes to avoid full payment of taxes and duties in connection with import entries of cigarettes from the Philippines during the period of July 2003 to June 2006. The government is seeking a fine of approximately THB 80.8 billion (approximately $2.53 billion). In May 2017, the King of Thailand signed a new customs act. The new act, which took effect in November 2017, substantially limits the amount of fines that Thailand could seek in these proceedings. PM Thailand believes that its declared import prices are in compliance with the Customs Valuation Agreement of the World Trade Organization and Thai law and that the allegations of the Public Prosecutor are inconsistent with several decisions already taken by Thai Customs and other Thai governmental agencies. Trial in the case began in November 2017. In March 2018, acting on a request from the Public Prosecutor, the court suspended the trial proceedings indefinitely and struck the case from the court list. In June 2018, the court reinstated the case and scheduled the remaining trial proceedings to resume in May 2019. The DSI also conducted an investigation into alleged underpayment by PM Thailand of customs duties and excise taxes relating to imports from Indonesia covering the period 2000-2003. On January 26, 2017, the Public Prosecutor filed charges against PM Thailand and its former Thai employee in the Bangkok Criminal Court alleging that PM Thailand and its former employee jointly and with the intention to defraud the Thai government under-declared import prices of cigarettes to avoid full payment of taxes and duties in connection with import entries during the period from January 2002 to July 2003. The government is seeking a fine of approximately THB 19.8 billion (approximately $620 million). In May 2017, the King of Thailand signed a new customs act. The new act, which took effect in November 2017, substantially limits the amount of fines that Thailand could seek in these proceedings. PM Thailand believes that its declared import prices are in compliance with the Customs Valuation Agreement of the World Trade Organization and Thai law, and that the allegations of the Public Prosecutor are inconsistent with several decisions already taken by Thai Customs and a Thai court. Trial in the case began in November 2018. The South Korean Board of Audit and Inspection (“BAI”) conducted an audit of certain Korean government agencies and the tobacco industry into whether inventory movements ahead of the January 1, 2015 increase of cigarette-related taxes by tobacco companies, including Philip Morris Korea Inc. ("PM Korea"), our South Korean affiliate, were in compliance with South Korean tax laws. In November 2016, the tax authorities completed their audit and assessed allegedly underpaid taxes and penalties. In order to avoid nonpayment financial costs, PM Korea paid approximately KRW 272 billion (approximately $238 million), of which KRW 100 billion (approximately $87.6 million) was paid in 2016 and KRW 172 billion (approximately $151 million) was paid in the first quarter of 2017. These amounts are included in other assets in the condensed consolidated balance sheets and in cash used in operating activities in the condensed consolidated statements of cash flows. PM Korea is appealing the assessments. The tax authorities have also referred the matter to the Public Prosecutor. On June 19, 2018, the Public Prosecutor decided not to file criminal charges against PM Korea and/or other alleged co-offenders. The Public Prosecutor also decided not to prosecute PM Korea and its managing director in connection with a criminal complaint against them that had been filed by the South Korean Ministry of Strategy and Finance (“MOSF”). In the criminal complaint, the MOSF alleged that PM Korea exceeded the monthly product withdrawal limits that the MOSF had set in its notice. On March 5, 2019, the Supreme Prosecutor's Office dismissed both the tax authorities' and the MOSF's appeals on the decisions of the Public Prosecutor, concluding the criminal investigations in these matters. A putative shareholder class action lawsuit, Rubenstahl v. Philip Morris International Inc., et al., was filed in December 2017, in the United States District Court for the District of New Jersey, purportedly on behalf of purchasers of Philip Morris International Inc. stock between July 26, 2016 and December 20, 2017. The lawsuit names Philip Morris International Inc. and certain officers as defendants and includes allegations that the defendants made false and/or misleading statements and/or failed to disclose information about PMI’s business, operations, financial condition, and prospects, related to alleged irregularities in clinical studies of PMI’s Platform 1 product. The lawsuit sought various forms of relief, including damages. On March 4, 2019, this lawsuit was voluntarily dismissed by the plaintiff due to similar allegations in the cases below. A putative shareholder class action lawsuit, City of Westland Police and Fire Retirement System v. Philip Morris International Inc., et al., was filed in September 2018, in the United States District Court for the Southern District of New York, purportedly on behalf of purchasers of Philip Morris International Inc. stock between February 8, 2018 and April 18, 2018. The lawsuit names Philip Morris International Inc. and certain officers as defendants and includes allegations that the defendants made false and/or misleading statements and/or failed to disclose information about PMI’s business, operations, financial condition, and prospects related to product sales, including those of PMI's Platform 1 products. The lawsuit seeks various forms of relief, including damages. We believe that this lawsuit is without merit and intend to defend it vigorously. In November 2018, the Court consolidated this lawsuit with the other putative shareholder class action lawsuits pending in the Southern District of New York. A putative shareholder class action lawsuit, Greater Pennsylvania Carpenters’ Pension Fund v. Philip Morris International Inc., et al., was filed in September 2018, in the United States District Court for the Southern District of New York, purportedly on behalf of purchasers of Philip Morris International Inc. stock between July 26, 2016 and April 18, 2018. The lawsuit names Philip Morris International Inc. and certain officers as defendants and seeks to combine the allegations and putative classes of the two cases discussed immediately above. The lawsuit seeks various forms of relief, including damages. We believe that this lawsuit is without merit and intend to defend it vigorously. A putative shareholder class action lawsuit, Gilchrist v. Philip Morris International Inc., et al., was filed in October 2018, in the United States District Court for the Southern District of New York, purportedly on behalf of purchasers of Philip Morris International Inc. stock between February 8, 2018 and April 18, 2018. The lawsuit names Philip Morris International Inc. and certain officers as defendants and includes allegations that the defendants made false and/or misleading statements and/or failed to disclose information about PMI's business, operations, financial condition, and prospects related to product sales, including those of PMI's Platform 1 products. The lawsuit seeks various forms of relief, including damages. We have not yet been served with the complaint, but believe this lawsuit is without merit and intend to defend it vigorously. We are also involved in additional litigation arising in the ordinary course of our business. While the outcomes of these proceedings are uncertain, management does not expect that the ultimate outcomes of other litigation, including any reasonably possible losses in excess of current accruals, will have a material adverse effect on our consolidated results of operations, cash flows or financial position. |
Income Taxes |
3 Months Ended |
---|---|
Mar. 31, 2019 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Income Taxes: Income tax provisions for jurisdictions outside the United States of America, as well as state and local income tax provisions, were determined on a separate company basis, and the related assets and liabilities were recorded in PMI’s condensed consolidated balance sheets. PMI’s effective tax rates for the three months ended March 31, 2019 and 2018 were 22.6% and 25.5%, respectively. The effective tax rate for the three months ended March 31, 2019 was favorably impacted by the reversal of a deferred tax liability on the unremitted earnings of PMI's Canadian subsidiary, RBH ($49 million) and by the Tax Cuts and Jobs Act. PMI estimates that its full-year 2019 effective tax rate will be approximately 23%. Changes in currency exchange rates, earnings mix by taxing jurisdiction or future regulatory developments may have an impact on the effective tax rates, which PMI monitors each quarter. Significant judgment is required in determining income tax provisions and in evaluating tax positions. PMI is regularly examined by tax authorities around the world and is currently under examination in a number of jurisdictions. The U.S. federal statute of limitations remains open for the years 2015 and onward. Foreign and U.S. state jurisdictions have statutes of limitations generally ranging from three to five years. It is reasonably possible that within the next 12 months certain tax examinations will close, which could result in a change in unrecognized tax benefits along with related interest and penalties. An estimate of any possible change cannot be made at this time. |
Indebtedness |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Disclosure [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Indebtedness | Indebtedness: Short-term Borrowings: PMI's short-term borrowings, consisting of commercial paper and bank loans to certain PMI subsidiaries at March 31, 2019 and December 31, 2018, had a carrying value of $1,551 million and $730 million, respectively. The fair value of PMI’s short-term borrowings, based on current market interest rates, approximates carrying value. Long-term Debt: At March 31, 2019 and December 31, 2018, PMI’s long-term debt consisted of the following:
Other foreign currency debt above includes mortgage debt in Switzerland and finance lease obligations at March 31, 2019 and December 31, 2018. Credit Facilities: On January 28, 2019, PMI entered into an agreement to extend the term of its $2.0 billion 364-day revolving credit facility from February 5, 2019, to February 4, 2020. At March 31, 2019, PMI's total committed credit facilities were as follows: (in billions)
At March 31, 2019, there were no borrowings under these committed credit facilities, and the entire committed amounts were available for borrowing. |
Fair Value Measurements |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Measurements | Fair Value Measurements: The authoritative guidance defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The guidance also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The guidance describes three levels of input that may be used to measure fair value, which are as follows:
Equity Securities The fair value of PMI’s equity securities, which are determined by using quoted prices in active markets, have been classified within Level 1. Derivative Financial Instruments PMI assesses the fair value of its foreign exchange contracts and interest rate contracts using standard valuation models that use, as their basis, readily observable market inputs. The fair value of PMI’s foreign exchange forward contracts is determined by using the prevailing foreign exchange spot rates and interest rate differentials, and the respective maturity dates of the instruments. The fair value of PMI’s currency options is determined by using a Black-Scholes methodology based on foreign exchange spot rates and interest rate differentials, currency volatilities and maturity dates. PMI’s derivative financial instruments have been classified within Level 2 in the table shown below. See Note 5. Financial Instruments for additional discussion of derivative financial instruments. Debt The fair value of PMI’s outstanding debt, which is utilized solely for disclosure purposes, is determined using quotes and market interest rates currently available to PMI for issuances of debt with similar terms and remaining maturities. The aggregate carrying value of PMI’s debt, excluding short-term borrowings and $36 million of finance leases, was $28,677 million at March 31, 2019. The fair value of PMI’s outstanding debt, excluding the aforementioned short-term borrowings and finance leases, was classified within Level 1 and Level 2 in the table shown below. The aggregate fair values of PMI’s equity securities, derivative financial instruments and debt as of March 31, 2019, were as follows:
|
Accumulated Other Comprehensive Losses |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Losses | Accumulated Other Comprehensive Losses: PMI’s accumulated other comprehensive losses, net of taxes, consisted of the following:
Reclassifications from Other Comprehensive Earnings The movements in accumulated other comprehensive losses and the related tax impact, for each of the components above, that are due to current period activity and reclassifications to the income statement, including those related to the deconsolidation of RBH, are shown on the condensed consolidated statements of comprehensive earnings for the three months ended March 31, 2019 and 2018. For additional information, see Note 3. Benefit Plans for disclosures related to PMI's pension and other benefits, Note 5. Financial Instruments for disclosures related to derivative financial instruments and Note 20. Deconsolidation of RBH for disclosures related to the deconsolidation of RBH. |
Balance Sheet Offsetting |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Offsetting [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance Sheet Offsetting | Balance Sheet Offsetting: Derivative Financial Instruments PMI uses foreign exchange contracts and interest rate contracts to mitigate its exposure to changes in exchange and interest rates from third-party and intercompany actual and forecasted transactions. Substantially all of PMI's derivative financial instruments are subject to master netting arrangements, whereby the right to offset occurs in the event of default by a participating party. While these contracts contain the enforceable right to offset through close-out netting rights, PMI elects to present them on a gross basis in the condensed consolidated balance sheets. Collateral associated with these arrangements is in the form of cash and is unrestricted. See Note 5. Financial Instruments for disclosures related to PMI's derivative financial instruments. The effects of these derivative financial instrument assets and liabilities on PMI's condensed consolidated balance sheets were as follows:
|
Investments in Unconsolidated Subsidiaries, Equity Securities and Other Related Parties |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity Method Investments and Joint Ventures [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investments in Unconsolidated Subsidiaries, Equity Securities and Other Related Parties | Investments in Unconsolidated Subsidiaries, Equity Securities and Other Related Parties: Investments in unconsolidated subsidiaries: At March 31, 2019 and December 31, 2018, PMI had total investments in unconsolidated subsidiaries of $1,024 million and $981 million, respectively, which were accounted for under the equity method of accounting. Equity method investments are initially recorded at cost. Under the equity method of accounting, the investment is adjusted for PMI's proportionate share of earnings or losses, dividends, capital contributions and movements in currency translation adjustments. The carrying value of our equity method investments at March 31, 2019 and December 31, 2018 exceeded our share of the unconsolidated subsidiaries' book value by $863 million and $835 million, respectively. The difference between the investment carrying value and the amount of underlying equity in net assets, excluding $821 million and $793 million attributable to goodwill as of March 31, 2019 and December 31, 2018, respectively, is being amortized on a straight-line basis over the underlying assets' estimated useful lives of 10 to 20 years. At March 31, 2019 and December 31, 2018, PMI received year-to-date dividends from unconsolidated subsidiaries of $16 million and $118 million, respectively. PMI holds a 23% equity interest in Megapolis Distribution BV, the holding company of CJSC TK Megapolis, PMI's distributor in Russia (Eastern Europe segment). PMI holds a 49% equity interest in United Arab Emirates-based Emirati Investors-TA (FZC) (“EITA”). PMI holds an approximate 25% economic interest in Société des Tabacs Algéro-Emiratie (“STAEM”), an Algerian joint venture that is 51% owned by EITA and 49% by the Algerian state-owned enterprise Management et Développement des Actifs et des Ressources Holding ("MADAR Holding"), formerly known as Société Nationale des Tabacs et Allumettes SpA. STAEM, which is part of the Middle East & Africa segment, manufactures and distributes under license some of PMI’s brands. The initial investments in Megapolis Distribution BV and EITA were recorded at cost and are included in investments in unconsolidated subsidiaries and equity securities on the condensed consolidated balance sheets. Equity securities: Following the deconsolidation of RBH, PMI recorded the continuing investment in RBH, PMI's wholly owned subsidiary, at fair value of $3,280 million at the date of deconsolidation, within investments in unconsolidated subsidiaries and equity securities. For further details, see Note 20. Deconsolidation of RBH. Transactions between PMI and RBH are considered to be related party transactions from the date of deconsolidation. For the period from the date of deconsolidation until March 31, 2019, transactions between PMI and RBH were not material. Other related parties: United Arab Emirates-based Trans-Emirates Trading and Investments (FZC) ("TTI") holds a 33% non-controlling interest in Philip Morris Misr LLC ("PMM"), an entity incorporated in Egypt which is consolidated in PMI’s financial statements in the Middle East & Africa segment. PMM sells, under license, PMI brands in Egypt through an exclusive distribution agreement with a local entity that is also controlled by TTI. Amounts in the tables below have been updated to reflect the transactions with this other related party for all periods. IPM India, PMI's consolidated subsidiary in the South & Southeast Asia segment, has a non-controlling interest of 43.7% held by Godfrey Phillips India Ltd, who also acts as contract manufacturer and distributor for IPM. Amounts in the tables below include transactions between these related parties, beginning in 2019. Prior periods do not include these transactions as they were not material. Financial activity with unconsolidated subsidiaries and other related parties: PMI’s net revenues with unconsolidated subsidiaries and the other related parties were as follows:
(a) Net revenues exclude excise taxes and VAT billed to customers. Prior year's amounts have been reclassified to conform with the current year's presentation. PMI’s balance sheet activity related to unconsolidated subsidiaries and the other related parties was as follows:
The activity primarily related to agreements with PMI’s unconsolidated subsidiaries and other related parties, which are in the ordinary course of business, and are primarily for distribution, contract manufacturing and licenses. PMI eliminated its respective share of all significant intercompany transactions with the equity method investees. |
Sale of Accounts Receivable |
3 Months Ended |
---|---|
Mar. 31, 2019 | |
Sale of Accounts Receivable [Abstract] | |
Sale of Accounts Receivable | Sale of Accounts Receivable: To mitigate risk and enhance cash and liquidity management PMI sells trade receivables to unaffiliated financial institutions. These arrangements allow PMI to sell, on an ongoing basis, certain trade receivables without recourse. The trade receivables sold are generally short-term in nature and are removed from the condensed consolidated balance sheets. PMI sells trade receivables under two types of arrangements, servicing and non-servicing. For servicing arrangements, PMI continues to service the sold trade receivables on an administrative basis and does not act on behalf of the unaffiliated financial institutions. When applicable, a servicing liability is recorded for the estimated fair value of the servicing. The amounts associated with the servicing liability were not material as of March 31, 2019 and March 31, 2018. Under the non-servicing arrangements, PMI does not provide any administrative support or servicing after the trade receivables have been sold to the unaffiliated financial institutions. Cumulative trade receivables sold, including excise taxes, for the three months ended March 31, 2019 and 2018, were $2,407 million and $2,509 million, respectively. PMI’s operating cash flows were positively impacted by the amount of the trade receivables sold and derecognized from the condensed consolidated balance sheets, which remained outstanding with the unaffiliated financial institutions. The trade receivables sold that remained outstanding under these arrangements as of March 31, 2019 and March 31, 2018, were $523 million, and $878 million, respectively. The net proceeds received are included in cash provided by operating activities in the condensed consolidated statements of cash flows. The difference between the carrying amount of the trade receivables sold and the sum of the cash received is recorded as a loss on sale of trade receivables within marketing, administration and research costs in the condensed consolidated statements of earnings. For the three months ended March 31, 2019 and 2018, the loss on sale of trade receivables was immaterial. |
Product Warranty |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Guarantees and Product Warranties [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Product Warranty | Product Warranty: PMI's IQOS devices are subject to standard product warranties generally for a period of 12 months from the date of purchase or such other periods as required by law. PMI generally provides in cost of sales for the estimated cost of warranty in the period the related revenue is recognized. PMI assesses the adequacy of its accrued product warranties and adjusts the amounts as necessary based on actual experience and changes in future estimates. Factors that affect product warranties may vary across markets but typically include product failure rates, logistics and service delivery costs, and warranty policies. PMI accounts for its product warranties within other accrued liabilities. At March 31, 2019 and December 31, 2018, these amounts were as follows:
|
Acquisitions |
3 Months Ended |
---|---|
Mar. 31, 2019 | |
Business Combinations [Abstract] | |
Acquisitions | Acquisitions: On March 21, 2018, PMI acquired the remaining 49% interest in Tabacalera Costarricense, S.A. and Mendiola y Compañía, S.A. for a net purchase price of $95 million, which includes $2 million of contingent consideration. As a result, PMI now owns 100% of these Costa Rican affiliates. The purchase of the remaining 49% interest resulted in a decrease to PMI’s additional paid-in capital of $86 million. |
Leases |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leases [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leases | Leases: PMI determines that a contract contains a lease if the contract conveys a right to control the use of the identified asset for a period of time in exchange for consideration. PMI’s operating leases are principally for real estate (office space, warehouses and retail store space) and vehicles. Lease expense is recognized on a straight-line basis over the lease term. Lease terms range from 1 year to 75 years, some of which include options to renew, which are reasonably certain to be renewed. Lease terms may also include options to terminate the lease. At lease commencement PMI recognizes lease liabilities and the corresponding right-of-use assets (at the present value of future payments) for predominately all of its operating leases. The recognition of the right of use asset and lease liability includes renewal options when it is reasonably certain that they will be exercised. The exercise of a lease renewal or termination option is at PMI’s discretion. Certain of PMI’s leases include payments that are based on changes to an index or on actual usage. These lease payments are adjusted periodically and are included within variable lease costs. For information regarding PMI’s immaterial finance leases, see Note 11. Fair Value Measurements. Beginning in 2019, PMI accounts for lease and nonlease components as a single lease component with the exception of its vehicle leases, of which PMI accounts for the lease components separately from the nonlease components. Additionally, leases with an initial term of 12 months or less are not included in the right of use asset or lease liability on the condensed consolidated statement of financial position. PMI’s operating leases at March 31, 2019 were as follows:
The components of PMI’s lease cost were as follows for the three months ended March 31, 2019:
For the three months ended March 31, 2019, lease costs of $19 million were recorded in cost of sales and $61 million were recorded in marketing, administration and research cost. Maturity of PMI’s operating lease liabilities, on an undiscounted basis, as of March 31, 2019, were as follows (as calculated under the new guidance ASC 842 (Leases)):
Minimum rental commitments under non-cancelable operating leases in effect at December 31, 2018, were as follows (as calculated under legacy guidance ASC 840 (Leases)):
Other information related to PMI’s operating leases were as follows for the three months ended March 31, 2019:
(1) PMI’s weighted-average discount rate is based on its estimated pre-tax cost of debt adjusted for country-specific risk. For further details, see Note 21. New Accounting Standards. |
Asset Impairment and Exit Costs |
3 Months Ended |
---|---|
Mar. 31, 2019 | |
Restructuring and Related Activities [Abstract] | |
Asset Impairment and Exit Costs | Asset Impairment and Exit Costs: As a part of global manufacturing footprint optimization, PMI recorded pre-tax asset impairment and exit costs of $20 million for the three months ended March 31, 2019, related to a plant closure in Pakistan. This total pre-tax charge was included in marketing, administration and research costs on the condensed consolidated statements of earnings and was included in the operating income of the South and Southeast Asia segment. |
Deconsolidation of RBH |
3 Months Ended |
---|---|
Mar. 31, 2019 | |
Deconsolidation [Abstract] | |
Deconsolidation of RBH | Deconsolidation of RBH: As discussed in Note 8. Contingencies, following the March 1, 2019 judgment of the Court of Appeal of Québec in two class action lawsuits against PMI's Canadian subsidiary, Rothmans, Benson & Hedges Inc. ("RBH"), PMI recorded in its consolidated results a pre-tax charge of $194 million, representing $142 million net of tax, in the first quarter of 2019. This pre-tax Canadian tobacco litigation-related expense was included in marketing, administration and research costs on PMI's condensed consolidated statement of earnings. The charge reflects PMI’s assessment of the portion of the judgment that it believes is probable and estimable at this time and corresponds to the trust account deposit required by the court. RBH’s share of the deposit is approximately CAD 257 million. On March 22, 2019, RBH obtained an initial order from the Ontario Superior Court of Justice granting it protection under the Companies’ Creditors Arrangement Act ("CCAA"), which is a Canadian federal law that permits a Canadian business to restructure its affairs while carrying on its business in the ordinary course with minimal disruption to its customers, suppliers and employees. The administration of the CCAA process, principally relating to the powers provided to the court and the court appointed monitor, removes certain elements of control of the business from both PMI and RBH. As a result, PMI has determined that it no longer has a controlling financial interest over RBH as defined in ASC 810 (Consolidation), and PMI deconsolidated RBH as of the date of the CCAA filing. PMI has also determined that it does not exert "significant influence" over RBH as that term is defined in ASC 323 (Investments-Equity Method and Joint Ventures). Therefore, PMI will account for its continuing investment in RBH in accordance with ASC 321 (Investments-Equity Securities) as an equity security, without readily determinable fair value. Following the deconsolidation, the carrying value of assets and liabilities of RBH was removed from the consolidated balance sheet of PMI, and the continuing investment in RBH was recorded at fair value at the date of deconsolidation. The total amount deconsolidated from PMI’s balance sheet was $3,519 million, including $1,323 million of cash, $1,463 million of goodwill, $529 million of accumulated other comprehensive earnings, primarily related to historical currency translation and $204 million of other assets and liabilities, net. While PMI is accounting for its investment in RBH as an equity security, PMI would recognize dividends as income upon receipt. However, while it remains under creditor protection, RBH does not anticipate paying dividends. The fair value of PMI’s continuing investment in RBH of $3,280 million was determined at the date of deconsolidation, recorded within Investments in unconsolidated subsidiaries and equity securities and will be assessed for impairment on an ongoing basis. The estimated fair value of the underlying business was determined based on an income approach using a discounted cash flow analysis, as well as a market approach for certain contingent liabilities. The information used in the estimate includes observable inputs, primarily a discount rate of 8%, a terminal growth rate of 2.5% and information about total tobacco market size in Canada and RBH’s share of the market, as well as unobservable inputs such as operating budgets and strategic plans, various inflation scenarios, estimated shipment volumes, and expected product pricing and projected margins. The difference between the carrying value of the assets and liabilities of RBH that were deconsolidated, and the fair value of the continuing investment, as determined at the date of deconsolidation, was $239 million, before tax, and this loss on deconsolidation is reflected within marketing, administration and research costs on PMI’s condensed consolidated statement of earnings for three months ended March 31, 2019. PMI also recorded a tax benefit of $49 million within the provision for income taxes, related to the reversal of a deferred tax liability on unremitted earnings of RBH. RBH is party to transactions with PMI and its consolidated subsidiaries entered into prior to deconsolidation in the normal course of business; these transactions include royalty payments and recharge of various corporate expenses for services benefiting RBH. Up to the date of CCAA filing, these transactions were eliminated on consolidation and had no impact on PMI’s consolidated statement of earnings. After deconsolidating RBH, these transactions are treated as third-party transactions in PMI’s financial statements. From the date of deconsolidation to March 31, 2019, the amount of these related party transactions was not material. Additionally PMI’s consolidated balance sheet included an immaterial amount of receivables from RBH at March 31, 2019. Developments in the CCAA process, including resolution through a plan of arrangement or compromise of all pending tobacco-related litigation currently stayed in Canada, as discussed in Note 8. Contingencies, could result in a material change in the fair value of PMI’s continuing investment in RBH. |
New Accounting Standards |
3 Months Ended |
---|---|
Mar. 31, 2019 | |
Accounting Changes and Error Corrections [Abstract] | |
New Accounting Standards | New Accounting Standards: Recently adopted On February 25, 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update ASU 2016-02, “Leases” (“ASU 2016-02”). ASU 2016-02 requires organizations that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. Additionally, ASU 2016-02 modifies current guidance for lessors' accounting. ASU 2016-02 is effective for interim and annual reporting periods beginning on or after January 1, 2019, with early adoption permitted. PMI has identified its lease management system and has identified and evaluated the applicable leases. In addition to the guidance in ASU 2016-02, PMI has evaluated ASU 2018-11, which was issued in July 2018 and provides an optional transitional method. As a result of this evaluation, PMI elected to use the optional transition method, which allows companies to use the effective date as the date of initial application on transition and not adjust comparative period financial information or make the new required disclosures for periods prior to the effective date. Additionally, PMI elected to use the hindsight practical expedient, as well as the package of practical expedients permitted under the transition guidance within the new standard. Upon adoption, PMI recognized lease liabilities and the corresponding right-of-use assets (at the present value of future payments) for predominately all of its operating leases in place at that time. At January 1, 2019, PMI's adoption of ASU 2016-02 resulted in an increase of approximately $0.7 billion on its assets and liabilities in its statement of financial position. ASU 2016-02 did not have a material impact on its results of operations or cash flows. For further details, see Note 18. Leases. On January 1, 2019, PMI elected to early adopt ASU 2018-15 “Intangibles - Goodwill and Other-Internal- Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract.” The adoption of ASU 2018-15 did not have a material impact on PMI's consolidated financial position or results of operations. |
New Accounting Standards (Policies) |
3 Months Ended |
---|---|
Mar. 31, 2019 | |
Accounting Changes and Error Corrections [Abstract] | |
New Accounting Standards | New Accounting Standards: Recently adopted On February 25, 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update ASU 2016-02, “Leases” (“ASU 2016-02”). ASU 2016-02 requires organizations that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. Additionally, ASU 2016-02 modifies current guidance for lessors' accounting. ASU 2016-02 is effective for interim and annual reporting periods beginning on or after January 1, 2019, with early adoption permitted. PMI has identified its lease management system and has identified and evaluated the applicable leases. In addition to the guidance in ASU 2016-02, PMI has evaluated ASU 2018-11, which was issued in July 2018 and provides an optional transitional method. As a result of this evaluation, PMI elected to use the optional transition method, which allows companies to use the effective date as the date of initial application on transition and not adjust comparative period financial information or make the new required disclosures for periods prior to the effective date. Additionally, PMI elected to use the hindsight practical expedient, as well as the package of practical expedients permitted under the transition guidance within the new standard. Upon adoption, PMI recognized lease liabilities and the corresponding right-of-use assets (at the present value of future payments) for predominately all of its operating leases in place at that time. At January 1, 2019, PMI's adoption of ASU 2016-02 resulted in an increase of approximately $0.7 billion on its assets and liabilities in its statement of financial position. ASU 2016-02 did not have a material impact on its results of operations or cash flows. For further details, see Note 18. Leases. On January 1, 2019, PMI elected to early adopt ASU 2018-15 “Intangibles - Goodwill and Other-Internal- Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract.” The adoption of ASU 2018-15 did not have a material impact on PMI's consolidated financial position or results of operations. |
Stock Plans (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of weighted average grant date fair value and compensation expense related to share-based awards | During the three months ended March 31, 2019 and 2018, shares granted to eligible employees, the grant date fair value per share and the recorded compensation expense related to PSU awards were as follows:
During the three months ended March 31, 2019 and 2018, shares granted to eligible employees, the weighted-average grant date fair value per share and the recorded compensation expense related to RSU awards were as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of assumptions used to determine the grant date fair value of the PSU awards subject to the TSR performance factor | The following assumptions were used to determine the grant date fair value of the PSU awards subject to the TSR performance factor:
(a) Based on the U.S. Treasury yield curve. (b) Determined using the observed historical volatility. (c) Determined using a weighted-average of historical and implied volatility. |
Benefit Plans (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Retirement Benefits [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Components of Pension and Other Employee Benefit Costs | Pension and other employee benefit costs per the condensed consolidated statements of earnings consisted of the following:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Components of Net Periodic Benefit Cost | Net periodic pension cost consisted of the following:
(1) Primarily non-U.S. based defined benefit retirement plans. |
Goodwill and Other Intangible Assets, net (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of movements in goodwill | The movements in goodwill were as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of amortizable intangible assets | Details of other intangible assets were as follows:
* Includes farmer contracts and intellectual property rights |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of non-amortizable intangible assets | Details of other intangible assets were as follows:
* Includes farmer contracts and intellectual property rights |
Financial Instruments (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value of Derivative Contracts | The fair value of PMI’s derivative contracts included in the condensed consolidated balance sheets as of March 31, 2019 and December 31, 2018, were as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cash Flow and Net Investment Hedging Activities Effect on Condensed Consolidated Statements of Earnings and Other Comprehensive Earnings | For the three months ended March 31, 2019 and 2018, PMI's cash flow and net investment hedging instruments impacted the condensed consolidated statements of earnings and comprehensive earnings as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Qualifying Hedging Activity Reported in Accumulated Other Comprehensive Earnings (Losses), Net of Income Taxes | Hedging activity affected accumulated other comprehensive losses, net of income taxes, as follows:
|
Earnings Per Share (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Calculation of Basic and Diluted EPS | Basic and diluted earnings per share (“EPS”) were calculated using the following:
|
Segment Reporting (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Data | Segment data were as follows:
Items affecting the comparability of results from operations were as follows:
PMI's net revenues by product category were as follows:
Note: Sum of product categories or Regions might not foot to total PMI due to roundings. |
Contingencies (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitments and Contingencies Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Tobacco Related Cases Pertaining to Combustible Products Pending Against Company | The table below lists the number of tobacco-related cases pertaining to combustible products pending against us and/or our subsidiaries or indemnitees as of April 23, 2019, April 24, 2018 and April 25, 2017:¹
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule Of Verdicts And Significant Post Trial Developments Where a Verdict was Returned In Favor of the Plaintiff(s) | The table below lists the verdict and significant post-trial developments in the four pending cases where a verdict was returned in favor of the plaintiff:
______ ¹ Includes cases pending in Canada.
|
Indebtedness (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Disclosure [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-Term Debt | At March 31, 2019 and December 31, 2018, PMI’s long-term debt consisted of the following:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Committed Credit Facilities | At March 31, 2019, PMI's total committed credit facilities were as follows: (in billions)
|
Fair Value Measurements (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Aggregate Fair Values of Equity Securities, Derivative Financial Instruments and Debt | The aggregate fair values of PMI’s equity securities, derivative financial instruments and debt as of March 31, 2019, were as follows:
|
Accumulated Other Comprehensive Losses (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Components of Accumulated Other Comprehensive Earnings (Losses), Net of Taxes | PMI’s accumulated other comprehensive losses, net of taxes, consisted of the following:
|
Balance Sheet Offsetting (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Offsetting [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Offsetting Assets | The effects of these derivative financial instrument assets and liabilities on PMI's condensed consolidated balance sheets were as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Offsetting Liabilities | The effects of these derivative financial instrument assets and liabilities on PMI's condensed consolidated balance sheets were as follows:
|
Investments in Unconsolidated Subsidiaries, Equity Securities and Other Related Parties (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity Method Investments and Joint Ventures [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings and Balance Sheet Activities with Unconsolidated Subsidiaries and Other Related Parties | PMI’s net revenues with unconsolidated subsidiaries and the other related parties were as follows:
(a) Net revenues exclude excise taxes and VAT billed to customers. Prior year's amounts have been reclassified to conform with the current year's presentation. PMI’s balance sheet activity related to unconsolidated subsidiaries and the other related parties was as follows:
|
Product Warranty (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Guarantees and Product Warranties [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Accrued Product Warranties | At March 31, 2019 and December 31, 2018, these amounts were as follows:
|
Leases (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leases [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Operating leases | Other information related to PMI’s operating leases were as follows for the three months ended March 31, 2019:
(1) PMI’s weighted-average discount rate is based on its estimated pre-tax cost of debt adjusted for country-specific risk. PMI’s operating leases at March 31, 2019 were as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Operating lease liability maturity | Maturity of PMI’s operating lease liabilities, on an undiscounted basis, as of March 31, 2019, were as follows (as calculated under the new guidance ASC 842 (Leases)):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lease cost components | The components of PMI’s lease cost were as follows for the three months ended March 31, 2019:
For the three months ended March 31, 2019, lease costs of $19 million were recorded in cost of sales and $61 million were recorded in marketing, administration and research cost. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Minimum rental commitments under non-cancelable operating leases in effect at December 31, 2018 | Minimum rental commitments under non-cancelable operating leases in effect at December 31, 2018, were as follows (as calculated under legacy guidance ASC 840 (Leases)):
|
Stock Plans (RSU Awards) (Details) - Restricted Stock Units (RSUs) [Member] - USD ($) $ / shares in Units, $ in Millions |
3 Months Ended | |
---|---|---|
Mar. 31, 2019 |
Mar. 31, 2018 |
|
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Number of Shares Granted (in shares) | 1,621,070 | 1,249,650 |
Weighted-Average Grant Date Fair Value Per RSU Award Granted (in dollars per share) | $ 77.13 | $ 100.70 |
Compensation expense for stock awards | $ 36 | $ 38 |
Benefit Plans (Components of Pension and Other Employee Benefits Costs) (Details) - USD ($) $ in Millions |
3 Months Ended | |
---|---|---|
Mar. 31, 2019 |
Mar. 31, 2018 |
|
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | ||
Total pension and other employee benefit costs | $ 21 | $ 6 |
Pension Plan [Member] | ||
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | ||
Total pension and other employee benefit costs | (5) | (16) |
Postemployment Benefit Plans [Member] | ||
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | ||
Total pension and other employee benefit costs | 24 | 19 |
Postretirement Benefit Costs [Member] | ||
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | ||
Total pension and other employee benefit costs | $ 2 | $ 3 |
Benefit Plans (Components of Net Periodic Benefit Cost) (Details) - Pension Plan [Member] - USD ($) $ in Millions |
3 Months Ended | |
---|---|---|
Mar. 31, 2019 |
Mar. 31, 2018 |
|
Defined Benefit Plan Disclosure [Line Items] | ||
Service cost | $ 54 | $ 53 |
Interest cost | 29 | 28 |
Expected return on plan assets | (79) | (87) |
Amortization: | ||
Net loss | 45 | 43 |
Prior service cost | 0 | 0 |
Net periodic pension cost | $ 49 | $ 37 |
Benefit Plans (Narrative) (Details) $ in Millions |
3 Months Ended |
---|---|
Mar. 31, 2019
USD ($)
| |
Retirement Benefits [Abstract] | |
Employer contributions | $ 17 |
Anticipated additional employer contributions during the remainder of the current fiscal year | $ 110 |
Financial Instruments (Qualifying Hedging Activity Reported in Accumulated Other Comprehensive Earnings (Losses) Net of Income Taxes) (Details) - USD ($) $ in Millions |
3 Months Ended | |
---|---|---|
Mar. 31, 2019 |
Mar. 31, 2018 |
|
Hedging Activity, Affecting Accumulated Other Comprehensive Income [Roll Forward] | ||
Derivative (gains)/losses transferred to earnings | $ (4) | $ 2 |
Change in fair value | (1) | (64) |
Other Comprehensive Income (Loss) [Member] | Derivative Contract [Member] | ||
Hedging Activity, Affecting Accumulated Other Comprehensive Income [Roll Forward] | ||
Gain as of January 1, | 35 | 42 |
Derivative (gains)/losses transferred to earnings | (4) | 2 |
Change in fair value | (1) | (64) |
Gain/(loss) as of March 31, | $ 30 | $ (20) |
Earnings Per Share (Calculation of Basic and Diluted EPS) (Details) - USD ($) $ in Millions |
3 Months Ended | |
---|---|---|
Mar. 31, 2019 |
Mar. 31, 2018 |
|
Earnings Per Share [Abstract] | ||
Net earnings attributable to PMI | $ 1,354 | $ 1,556 |
Less distributed and undistributed earnings attributable to share-based payment awards | 4 | 3 |
Net earnings for basic and diluted EPS | $ 1,350 | $ 1,553 |
Weighted-average shares for basic EPS (in shares) | 1,555,000,000 | 1,553,000,000 |
Plus contingently issuable performance stock units (PSUs) (in shares) | 1,000,000 | 1,000,000 |
Weighted-average shares for diluted EPS (in shares) | 1,556,000,000 | 1,554,000,000 |
Antidilutive stock awards (in shares) | 0 | 0 |
Contingencies (Tobacco-Related Litigation) (Details) |
Mar. 31, 2019
litigation_case
|
---|---|
Loss Contingencies [Line Items] | |
Number of cases decided in favor of PM | 493 |
Number of cases decided in favor of plaintiff | 13 |
Cases Remaining On Appeal [Member] | |
Loss Contingencies [Line Items] | |
Cases on appeal | 4 |
Case Decided In Favor Of Plaintiff [Member] | |
Loss Contingencies [Line Items] | |
Number of cases that reached final resolution in favor of PM | 9 |
Contingencies (Verdicts and Post-Trial Developments) (Details) |
1 Months Ended | 3 Months Ended | |||||||
---|---|---|---|---|---|---|---|---|---|
Mar. 01, 2019
CAD ($)
|
Mar. 01, 2019
USD ($)
|
Aug. 05, 2016
ARS ($)
|
Aug. 05, 2016
USD ($)
|
May 27, 2015
CAD ($)
|
May 27, 2015
USD ($)
|
Apr. 30, 2004
BRL (R$)
|
Apr. 30, 2004
USD ($)
|
Mar. 31, 2019 |
|
Brazil [Member] | Smoking And Health Class Actions [Member] | The Smoker Health Defense Association (ADESF) [Member] | |||||||||
Loss Contingencies [Line Items] | |||||||||
Smoking and health loss contingency interest rate (percentage per month) | 1.00% | 1.00% | |||||||
Brazil [Member] | Smoking And Health Class Actions [Member] | Award per smoker per year [Member] | The Smoker Health Defense Association (ADESF) [Member] | |||||||||
Loss Contingencies [Line Items] | |||||||||
Damages awarded | R$ 1,000 | $ 255 | |||||||
Brazil [Member] | Smoking And Health Class Actions [Member] | Cases With Verdicts And Post Trial Developments [Member] | The Smoker Health Defense Association (ADESF) [Member] | |||||||||
Loss Contingencies [Line Items] | |||||||||
Date | February 2004 | ||||||||
Verdict | The Civil Court of São Paulo found defendants liable without hearing evidence. In April 2004, the court awarded “moral damages” of R$1,000 (approximately $255) per smoker per full year of smoking plus interest at the rate of 1% per month, as of the date of the ruling. The court did not assess actual damages, which were to be assessed in a second phase of the case. The size of the class was not defined in the ruling. | ||||||||
Post-Trial Developments | Defendants appealed to the São Paulo Court of Appeals, which annulled the ruling in November 2008, finding that the trial court had inappropriately ruled without hearing evidence and returned the case to the trial court for further proceedings. In May 2011, the trial court dismissed the claim. In March 2017, plaintiff filed an en banc appeal to the Superior Court of Justice. In addition, the defendants filed a constitutional appeal to the Federal Supreme Tribunal on the basis that plaintiff did not have standing to bring the lawsuit. Both appeals are still pending. | ||||||||
Canada [Member] | Smoking And Health Class Actions [Member] | Cases With Verdicts And Post Trial Developments [Member] | Cecilia Letourneau [Member] | |||||||||
Loss Contingencies [Line Items] | |||||||||
Date | May 27, 2015 | ||||||||
Verdict | On May 27, 2015, the Superior Court of the District of Montreal, Province of Quebec ruled in favor of the Létourneau class on liability and awarded a total of CAD 131 million (approximately $98.1 million) in punitive damages, allocating CAD 46 million (approximately $34.4 million) to RBH. The trial court ordered defendants to pay the full punitive damage award into a trust within 60 days. The court did not order the payment of compensatory damages. | ||||||||
Post-Trial Developments | In June 2015, RBH commenced the appellate process with the Court of Appeal of Quebec. On March 1, 2019, the Court of Appeal issued a decision largely affirming the trial court's decision. (See “Stayed Litigation — Canada” for further detail.) | ||||||||
Canada [Member] | Smoking And Health Class Actions [Member] | Cases With Verdicts And Post Trial Developments [Member] | Conseil Quebecois Sur Le Tabac Et La Sante and Jean-Yves Blais [Member] | |||||||||
Loss Contingencies [Line Items] | |||||||||
Date | May 27, 2015 | ||||||||
Verdict | On May 27, 2015, the Superior Court of the District of Montreal, Province of Quebec ruled in favor of the Blais class on liability and found the class members’ compensatory damages totaled approximately CAD 15.5 billion (approximately $11.6 billion), including pre-judgment interest. The trial court awarded compensatory damages on a joint and several liability basis, allocating 20% to our subsidiary (approximately CAD 3.1 billion including pre-judgment interest (approximately $2.32 billion)). The trial court awarded CAD 90,000 (approximately $67,370) in punitive damages, allocating CAD 30,000 (approximately $22,460) to our subsidiary. The trial court ordered defendants to pay CAD 1 billion (approximately $748.6 million) of the compensatory damage award, CAD 200 million (approximately $149.7 million) of which is our subsidiary’s portion, into a trust within 60 days. | ||||||||
Post-Trial Developments | In June 2015, RBH commenced the appellate process with the Court of Appeal of Quebec. On March 1 2019, the Court of Appeal issued a decision largely affirming the trial court's decision. (See “Stayed Litigation — Canada” for further detail.) | ||||||||
Canada [Member] | Smoking And Health Class Actions [Member] | Cecilia Letourneau [Member] | Judicial Ruling [Member] | Imperial Tobacco Ltd., Rothmans, Benson And Hedges Inc., And JTI Macdonald Corp. [Member] | |||||||||
Loss Contingencies [Line Items] | |||||||||
Punitive damages awarded | $ 131,000,000 | $ 98,100,000 | |||||||
Canada [Member] | Smoking And Health Class Actions [Member] | Cecilia Letourneau [Member] | Judicial Ruling [Member] | RBH [Member] | |||||||||
Loss Contingencies [Line Items] | |||||||||
Punitive damages awarded | $ 46,000,000 | $ 34,400,000 | |||||||
Payment period for awarded punitive damages to be deposited into trust | 60 days | 60 days | |||||||
Canada [Member] | Smoking And Health Class Actions [Member] | Conseil Quebecois Sur Le Tabac Et La Sante and Jean-Yves Blais [Member] | Judicial Ruling [Member] | Imperial Tobacco Ltd., Rothmans, Benson And Hedges Inc., And JTI Macdonald Corp. [Member] | |||||||||
Loss Contingencies [Line Items] | |||||||||
Punitive damages awarded | $ 90,000 | $ 67,370 | |||||||
Compensatory damages awarded | 15,500,000,000 | 11,600,000,000 | |||||||
Awarded compensatory damages that are to be deposited into trust | 1,000,000,000 | 748,600,000 | |||||||
Canada [Member] | Smoking And Health Class Actions [Member] | Conseil Quebecois Sur Le Tabac Et La Sante and Jean-Yves Blais [Member] | Judicial Ruling [Member] | RBH [Member] | |||||||||
Loss Contingencies [Line Items] | |||||||||
Punitive damages awarded | 30,000 | 22,460 | |||||||
Compensatory damages awarded | $ 2,700,000,000 | $ 2,020,000,000 | $ 3,100,000,000 | $ 2,320,000,000 | |||||
Damages allocated to subsidiary (percent) | 20.00% | 20.00% | 20.00% | 20.00% | |||||
Awarded compensatory damages that are to be deposited into trust | $ 200,000,000 | $ 149,700,000 | |||||||
Payment period for compensatory damages to be deposited into trust | 60 days | 60 days | |||||||
Argentina [Member] | Individual Action [Member] | Cases With Verdicts And Post Trial Developments [Member] | Hugo Lespada [Member] | |||||||||
Loss Contingencies [Line Items] | |||||||||
Date | August 5, 2016 | ||||||||
Verdict | On August 5, 2016, the Civil Court No. 14 - Mar del Plata, issued a verdict in favor of plaintiff, an individual smoker, and awarded him ARS 110,000 (approximately $2,628), plus interest, in compensatory and moral damages. The trial court found that our subsidiary failed to warn plaintiff of the risk of becoming addicted to cigarettes. | ||||||||
Post-Trial Developments | On August 23, 2016, our subsidiary filed its notice of appeal. On October 31, 2017, the Civil and Commercial Court of Appeals of Mar del Plata ruled that plaintiff's claim was barred by the statute of limitations and it reversed the trial court's decision. On November 28, 2017, plaintiff filed an extraordinary appeal of the reversal of the trial court's decision to the Supreme Court of the Province of Buenos Aires. | ||||||||
Argentina [Member] | Individual Action [Member] | Hugo Lespada [Member] | Judicial Ruling [Member] | |||||||||
Loss Contingencies [Line Items] | |||||||||
Compensatory damages awarded | $ 110,000 | $ 2,628 |
Contingencies (Public Civil Actions) (Details) - Combustible Products [Member] - Public Civil Actions [Member] - litigation_case |
Apr. 23, 2019 |
Apr. 24, 2018 |
Apr. 25, 2017 |
---|---|---|---|
Loss Contingencies [Line Items] | |||
Cases brought against PM | 2 | 2 | |
Subsequent Event [Member] | |||
Loss Contingencies [Line Items] | |||
Cases brought against PM | 2 | ||
Subsequent Event [Member] | Argentina [Member] | |||
Loss Contingencies [Line Items] | |||
Cases brought against PM | 1 | ||
Subsequent Event [Member] | Venezuela [Member] | |||
Loss Contingencies [Line Items] | |||
Cases brought against PM | 1 |
Contingencies (Other Litigation) (Details) - Other Litigation [Member] $ in Millions, ₩ in Billions, ฿ in Billions |
3 Months Ended | 5 Months Ended | 12 Months Ended | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Jan. 26, 2017
THB (฿)
|
Jan. 26, 2017
USD ($)
|
Jan. 18, 2016
THB (฿)
defendant
|
Jan. 18, 2016
USD ($)
defendant
|
Mar. 31, 2017
KRW (₩)
|
Mar. 31, 2017
USD ($)
|
Mar. 31, 2017
KRW (₩)
|
Mar. 31, 2017
USD ($)
|
Dec. 31, 2016
KRW (₩)
|
Dec. 31, 2016
USD ($)
|
|
Thailand [Member] | The Department of Special Investigations of the Government of Thailand [Member] | ||||||||||
Loss Contingencies [Line Items] | ||||||||||
Loss contingency, damages sought, value | ฿ 19.8 | $ 620.0 | ||||||||
Thailand [Member] | The Department of Special Investigations of the Government of Thailand [Member] | Pending Litigation [Member] | ||||||||||
Loss Contingencies [Line Items] | ||||||||||
Number of defendants | 8 | 8 | ||||||||
Loss contingency, damages sought, value | ฿ 80.8 | $ 2,530.0 | ||||||||
Korea [Member] | The South Korean Board Of Audit And Inspection [Member] | ||||||||||
Loss Contingencies [Line Items] | ||||||||||
Amounts paid | ₩ 172 | $ 151.0 | ₩ 272 | $ 238.0 | ₩ 100 | $ 87.6 |
Income Taxes (Details) - USD ($) $ in Millions |
3 Months Ended | 12 Months Ended | |
---|---|---|---|
Mar. 31, 2019 |
Mar. 31, 2018 |
Dec. 31, 2019 |
|
Income Taxes [Line Items] | |||
Effective tax rate | 22.60% | 25.50% | |
Tax benefit for reversal of deferred tax liabilities | $ 49 | ||
Scenario, Forecast [Member] | |||
Income Taxes [Line Items] | |||
Effective tax rate | 23.00% |
Indebtedness (Narrative) (Details) - USD ($) |
Mar. 31, 2019 |
Jan. 28, 2019 |
Dec. 31, 2018 |
---|---|---|---|
Line of Credit Facility [Line Items] | |||
Short-term borrowings, carrying value | $ 1,551,000,000 | $ 730,000,000 | |
Committed credit facilities | 8,000,000,000 | ||
Borrowings under committed credit facilities | 0 | ||
364-day revolving credit expiring February 4, 2020 [Member] | |||
Line of Credit Facility [Line Items] | |||
Committed credit facilities | $ 2,000,000,000 | $ 2,000,000,000 |
Indebtedness (Credit Facilities) (Details) - USD ($) $ in Billions |
Jan. 28, 2019 |
Mar. 31, 2019 |
---|---|---|
Line of Credit Facility [Line Items] | ||
Committed credit facilities | $ 8.0 | |
Multi-year revolving credit, expiring February 28, 2021 [Member] | ||
Line of Credit Facility [Line Items] | ||
Committed credit facilities | 2.5 | |
Multi-year revolving credit, expiring October 1, 2022 [Member] | ||
Line of Credit Facility [Line Items] | ||
Committed credit facilities | 3.5 | |
364-day revolving credit expiring February 4, 2020 [Member] | ||
Line of Credit Facility [Line Items] | ||
Committed credit facilities | $ 2.0 | $ 2.0 |
Debt Instrument, Term | 364 days |
Fair Value Measurements (Narrative) (Details) $ in Millions |
Mar. 31, 2019
USD ($)
|
---|---|
Fair Value Disclosures [Abstract] | |
Finance lease obligations, carrying value | $ 36 |
Debt excluding short-term borrowings and capital lease obligations, carrying value | $ 28,677 |
Fair Value Measurements (Aggregate Fair Value of Derivative Financial Instruments, Equity Securities and Debt (Details) $ in Millions |
Mar. 31, 2019
USD ($)
|
---|---|
Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) [Member] | |
Assets: | |
Equity securities | $ 320 |
Derivative contracts | 0 |
Total assets | 320 |
Liabilities: | |
Debt | 29,626 |
Derivative contracts | 0 |
Total liabilities | 29,626 |
Significant Other Observable Inputs (Level 2) [Member] | |
Assets: | |
Equity securities | 0 |
Derivative contracts | 359 |
Total assets | 359 |
Liabilities: | |
Debt | 161 |
Derivative contracts | 566 |
Total liabilities | 727 |
Significant Unobservable Inputs (Level 3) [Member] | |
Assets: | |
Equity securities | 0 |
Derivative contracts | 0 |
Total assets | 0 |
Liabilities: | |
Debt | 0 |
Derivative contracts | 0 |
Total liabilities | 0 |
Fair Value [Member] | |
Assets: | |
Equity securities | 320 |
Derivative contracts | 359 |
Total assets | 679 |
Liabilities: | |
Debt | 29,787 |
Derivative contracts | 566 |
Total liabilities | $ 30,353 |
Balance Sheet Offsetting (Details) - Derivative Contract [Member] - USD ($) $ in Millions |
Mar. 31, 2019 |
Dec. 31, 2018 |
---|---|---|
Assets | ||
Gross Amounts Recognized | $ 359 | $ 220 |
Gross Amount Offset in the Condensed Consolidated Balance Sheet | 0 | 0 |
Net Amounts Presented in the Condensed Consolidated Balance Sheet | 359 | 220 |
Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet, Financial Instruments | (291) | (124) |
Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet, Cash Collateral Received/Pledged | (46) | (80) |
Net Amount | 22 | 16 |
Liabilities | ||
Gross Amounts Recognized | 566 | 631 |
Gross Amount Offset in the Condensed Consolidated Balance Sheet | 0 | 0 |
Net Amounts Presented in the Condensed Consolidated Balance Sheet | 566 | 631 |
Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet, Financial Instruments | (291) | (124) |
Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet, Cash Collateral Received/Pledged | (268) | (427) |
Net Amount | $ 7 | $ 80 |
Investments in Unconsolidated Subsidiaries, Equity Securities and Other Related Parties (Balance sheet and earnings activity) (Details) - USD ($) $ in Millions |
3 Months Ended | ||
---|---|---|---|
Mar. 31, 2019 |
Mar. 31, 2018 |
Dec. 31, 2018 |
|
Schedule of Equity Method Investments [Line Items] | |||
Net revenues | $ 572 | $ 521 | |
Receivables | 584 | $ 308 | |
Payables | 59 | 8 | |
Megapolis Group | |||
Schedule of Equity Method Investments [Line Items] | |||
Net revenues | 359 | 357 | |
Receivables | 434 | 172 | |
Payables | 2 | 0 | |
Other | |||
Schedule of Equity Method Investments [Line Items] | |||
Net revenues | 213 | $ 164 | |
Receivables | 150 | 136 | |
Payables | $ 57 | $ 8 |
Sale of Accounts Receivable (Details) - USD ($) $ in Millions |
3 Months Ended | ||
---|---|---|---|
Mar. 31, 2019 |
Mar. 31, 2018 |
Dec. 31, 2018 |
|
Sale of Accounts Receivable [Abstract] | |||
Servicing liability | $ 0 | $ 0 | |
Trade receivables sold and derecognized from the Consolidated Balance Sheets | 2,407 | 2,509 | |
Trade receivables sold and derecognized that remain uncollected | 523 | $ 878 | |
Loss on sale of trade receivables | $ 0 | $ 0 |
Product Warranty (Narrative) (Details) |
3 Months Ended |
---|---|
Mar. 31, 2019 | |
Guarantees and Product Warranties [Abstract] | |
Standard product warranty term | 12 months |
Product Warranty (Movement in Product Warranty Obligations) (Details) - USD ($) $ in Millions |
3 Months Ended | |
---|---|---|
Mar. 31, 2019 |
Mar. 31, 2018 |
|
Movement in Standard Product Warranty Accrual [Roll Forward] | ||
Balance at beginning of period | $ 67 | $ 71 |
Changes due to: | ||
Warranties issued | 78 | 179 |
Settlements | (39) | $ (183) |
Balance at end of period | $ 106 |
Acquisitions (Narrative) (Details) - Tabacalera Costarricense, S.A. And Mendiola Y Campania, S.A. Purchase Of Noncontrolling Interest [Member] $ in Millions |
Mar. 21, 2018
USD ($)
|
---|---|
Business Acquisition [Line Items] | |
Interest acquired | 49.00% |
Net purchase price | $ 95 |
Contingent consideration | $ 2 |
Ownership percentage | 100.00% |
Decrease to additional paid-in capital | $ 86 |
Asset Impairment and Exit Costs (Details) $ in Millions |
3 Months Ended |
---|---|
Mar. 31, 2019
USD ($)
| |
Restructuring and Related Activities [Abstract] | |
Pre-tax asset impairment and exit costs | $ 20 |
New Accounting Standards (Leases) (Details) $ in Billions |
Jan. 01, 2019
USD ($)
|
---|---|
Accounting Standards Update 2016-02 [Member] | |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |
Operating Lease, Liability and Right-of-Use Asset | $ 0.7 |
O6R@RCF5,F-\6HW/*/%I-1B]E] O@*IG;&+AM1B?
M5N-3@G%M-1@ID'*C5=9D"418C$^KD\Z8&KP8>58C+TKD60TS+[.- HAR3BS<
M%@//:N!%"3P+@,=>36NMZA.^5-]BX%D-O"B!9S7+ **F@YKWT3V9X@*F>#Y1,Q7^%*T@,#THP
M1VFDBRLI>^>-FEA0BN*OXRYTW(?Q9I].L'5 ,@&2&7"(>=B8*"K_Q#TO,FL&
M8L?>=SP\\?:88&_*X(RMB' +>
M!+$X31RM6P.Q_O Y-SRE'">.@\21R2^<%1Y.$(NSPM':-! [&_W.YSA/'.2)
M#)T23@*YX\423@*AE:&PO=V]R:W-H965T-VA7N0,A"AC)>)D\XI
M W!Y?F?_'&O'6B[&PO=V]R:W-H
M965T
\IJ:$1@PI/
M=OP
H7B'WDO.]]&181AB0W+$,/2YYEYTQH*RH@AD=BP1(:)Q9;$AF6$88D-RQ##
MTN>9NX1!C"%.L"0>J1%AXB%#8L(R@K#$A&4(80E6RHRY#QDH*LT(Q!(CE@&(
MI>]32O?1&P5Q:G0Q8@D0,V*:EABQC$"L,&(5@EB!E;)_@E 4>8(49JP 8T:E
MP(Q5!&.%&:L0QLHGZEXE/PWYV!",6 '$C%B.*^*]5P1BA1&K$,0*\!3<>WD&
MHE1.G6",6 4@5LBGNRH 08I10X,1*X28>-A1&+&*0*PQ8AV"6/L\M7#O.R#(
M".+&HS%AC0@3-W.-">L(PAH3UB&$M>]39^ZT!H(R1?4',]:(,=4?S%A',-;$
M:^<0QMH'JI7[Y@0$&6JQI3%B'8!8^SY_89G[:@M$<49=LEBQ1HJI5_I8L8Y0
M;+!B$Z+8 ,72'1(09*AG?(,5&Z28&%6#%9L(Q08K-B&*#5#L#L@4
EO=K)((Z6'Q=XI\T)$V[HH31SNNH&31G%FKQ;U
MW$NQ6LBC2N),O!16>4S3J/B[%HD\+VUF7R=>X_U!51/.:I%'>_%#J)_Y2Z%'
M3LNRC5.1E;',K$+LEO8G]OA,8550(W[%XES>W%N5E#